

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2595948 T3**

-
- (51) Int.Cl.: **C 07 C 67/08 (2006.01)** **C 07 C 67/297 (2006.01)** **C 07 C 69/533 (2006.01)**
C 07 D 319/08 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2019-10-21**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-09-04**
- (86) Europæisk ansøgning nr.: **11738152.5**
- (86) Europæisk indleveringsdag: **2011-07-08**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-05-29**
- (86) International ansøgning nr.: **DK2011000081**
- (87) Internationalt publikationsnr.: **WO2012010172**
- (30) Prioritet: **2010-07-20 US 366018 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **LEO LABORATORIES LIMITED, 285 Cashel Road , Crumlin, Dublin 2, Irland**
- (72) Opfinder: **HÖGBERG, Thomas, Leo Pharma A/S, Industriparken 55, 2750 Ballerup, Danmark**
LIANG, Xifu, Leo Pharma A/S, Industriparken 55, 2750 Ballerup, Danmark
HORNEMAN, Anne, Marie, Leo Pharma A/S, Industriparken 55, 2750 Ballerup, Danmark
PETERSEN, Anders, Klarskov, Leo Pharma A/S, Industriparken 55, 2750 Ballerup, Danmark
GRUE-SØRENSEN, Gunnar, Thyrasvej 3, 4000 Roskilde, Danmark
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **FREM GANGSMÅDE TIL FREMSTILLING AF INGENOL-3-ANGELAT**
- (56) Fremdragne publikationer:
CA-A1- 2 541 903
MITSURU HIROTA ET AL: "New ingenol-esters as piscicidal constituents of Euphorbia cotinifolia L.", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 44, no. 6, 1 January 1980 (1980-01-01), pages 1351-1356, XP55006372, ISSN: 0002-1369, DOI: 10.1271/bbb1961.44.1351
D UEMURA: "Isolation and structures of irritant substances obtained from ? species ?", TETRAHEDRON LETTERS, vol. 14, no. 11, 1 January 1973 (1973-01-01), pages 881-884, XP55006201, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(01)95742-9
BERND SORG UND ERICH HECKER*: "Zur Chemie des Ingenols, II [1] Ester des Ingenols und des L17.8-Isoingenols", ZEITSCHRIFT FÜR NATURFORSCHUNG, TEIL B:ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FÜR NATURFORSCHUNG. TUBINGEN, DE, vol. 37b, 1 January 1982 (1982-01-01), pages 748-756, XP008142493, ISSN: 0932-0776 & OPFERKUCH H J ET AL: "Zur Chemie des Ingenols, I Ingenol und einige 8einer Derivate", ZEITSCHRIFT FÜR NATURFORSCHUNG. TEIL B, ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FÜR NATURFORSCHUNG, TUEBINGEN, DE, vol. 36b, 1 January 1981 (1981-01-01), pages 878-887, XP008142492, ISSN: 0340-5087

Fortsættes ...

Giovanni Appendino ET AL: "Synthesis of Modified Ingenol Esters", European Journal of Organic Chemistry, 15 October 1999 (1999-10-15), pages 3413-3420, XP55006092, DOI: 10.1002/(SICI)1099-0690(199912)1999:12<3413::AID-EJOC3413>3.0.CO;2-S Retrieved from the Internet: URL:[http://onlinelibrary.wiley.com/doi/10.1002/\(SICI\)1099-0690\(199912\)1999:12<3413::AID-EJOC3413>3.0.CO;2-S/](http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1099-0690(199912)1999:12<3413::AID-EJOC3413>3.0.CO;2-S/) [retrieved on 2011-09-01] cited in the application

KIO A. ABO ET AL: "Ingenol esters from the pro-inflammatory fraction of *Euphorbia kamerunica*", PHYTOCHEMISTRY, vol. 21, no. 3, 1 January 1982 (1982-01-01), pages 725-726, XP55006203, ISSN: 0031-9422, DOI: 10.1016/0031-9422(82)83174-9

BALOGH I B ET AL: "Bio-active compounds from *Euphorbia cornigera* Boiss", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 44, no. 8, 1 August 2009 (2009-08-01), pages 3188-3194, XP026108434, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2009.03.019 [retrieved on 2009-03-26]

Benoît Hartmann ET AL: "Improved preparation of angelate esters", Tetrahedron Letters, vol. 32, no. 38, 1 September 1991 (1991-09-01), pages 5077-5080, XP055593549, AMSTERDAM, NL ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)93432-4

Robert E. Buckles ET AL: "THE PREPARATION OF TIGLIC AND ANGELIC ACIDS AND ESTERS 1", JOURNAL OF ORGANIC CHEMISTRY, vol. 15, no. 3, 1 May 1950 (1950-05-01), pages 680-684, XP055593497, US ISSN: 0022-3263, DOI: 10.1021/jo01149a038

Benoît Hartmann ET AL: "Improved preparation of angelate esters", Tetrahedron Letters, vol. 32, no. 38, 1 September 1991 (1991-09-01), pages 5077-5080, XP055593549, AMSTERDAM, NL ISSN: 0040-4039, DOI: 10.1016/S0040-4039(00)93432-4

DESCRIPTION

FIELD OF THE INVENTION

[0001] The present invention relates to methods of producing ingenol-3-angelate (2-methyl-2(Z)-butenoic acid (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester; PEP005, ingenol mebutate) from ingenol. The present disclosure further provides novel intermediates and methods for the synthesis of the intermediates useful for producing ingenol-3-angelate.

BACKGROUND OF THE INVENTION

[0002] Ingenol-3-angelate (PEP005, ingenol mebutate) is a protein kinase C activator in phase III clinical development for the treatment of actinic keratosis. The drug candidate is also in phase II trials for non-melanoma skin cancer [Ogbourne, S. M.; *Anti-cancer Drugs*, (2007), 18, 357-62].

[0003] The compound ingenol-3-angelate (PEP005) [Sayed, M.D. et.al.; *Experienta*, (1980), 36, 1206-1207] can be isolated from various *Euphorbia* species, and particularly from *Euphorbia peplus* [Hohmann, J. et. al; *Planta Med.*, (2000), 66, 291-294] and *Euphorbia drummondii* by extraction followed by chromatography as described in US 7449492. According to this procedure, extraction of 17 kg of fresh *Euphorbia peplus* affords 7 g of a crude oil, which subsequently must be purified by HPLC to afford pure ingenol-3-angelate. The purification method is not ideally suited for larger scale production, as chlorophyll, which otherwise would co-migrate with ingenol-3-angelate, must be removed from the extract before the final purification step. Thus, the yield of ingenol-3-angelate by extraction from *Euphorbia peplus* and subsequent chromatography is extremely low. Therefore an alternative process for the production of ingenol-3-angelate which is also suitable for larger scale production would be desirable. Ingenol is a natural product which is easily extracted from the readily available seeds of *Euphorbia lathyris* [Appendino, G. et. al., *J. Nat. Prod.* (1999), 62, 76-79]. As part of the extraction procedure the various ingenol esters present are hydrolysed and thus the amount of isolated ingenol is increased, making ingenol more readily available than ingenol-3-angelate [Appendino, G. et. al., *J. Nat. Prod.* (1999), 62, 76-79; Girin, M.A. et. al., *J. Chromatogr.*, (1993), 637, 206-208].

[0004] Ingenol or ingenol esters may also be found in other *Euphorbia* species, for example ingenol or ingenol esters have also been found in *E. acruensis*, *E. antiquorum*, *E. biglandulosa*, *E. canariensis*, *E. cooperi*, *E. cotinifolia*, *E. deightonii*, *E. desmondi*, *E. drupifera*, *E. ebracteolata*, *E. esula*, *E. helioscopia*, *E. hermentiana*, *E. iberica*, *E. ingens*, *E. jolkini*, *E. kamerunica*, *E. kansui*, *E. leuconeura*, *E. matabelensis*, *E. megalantha*, *E. millii*, *E. myrsinites*,

E. nematocypha, *E. nubica*, *E. palustris*, *E. peplus*, *E. petiolata*, *E. pilosa*, *E. quadrialata*, *E. quinquecostata*, *E. resinifera*, *E. royleana*, *E. seguieriana*, *E. serrata*, *E. sieboldiana*, *E. tirucalli*, *E. triangularis*, *E. trigona*.

Furthermore, ingenol is commercially available, for example from LC Laboratories, 165 New Boston Street, Woburn, MA 01801, USA.

Ingenol has previously been used as a starting point for the semi-synthetic preparation of ingenol-3-esters [Sorg, B. et. al, Z. Naturforsch., (1982), 37B, 748-756] and ingenol-3-ester derivatives [Appendino et. al., Eur. J. Org. Chem. (1999), 3413; Opferkuch et.al., Z. Naturforschung, (1981), 36B, 878]. However, the preparation of ingenol-3-angelate and ingenol-3-angelate derivatives from ingenol has not been described. The preparation of angelate esters is not straightforward as angelic acid and angelate esters are prone to isomerisation of the double bond to form the tiglate ester, both with and without the presence of base [Beeby, P., Tetrahedron Lett. (1977), 38, 3379-3382, Hoskins, W.M., J. Chem. Soc. Perkin Trans. 1, (1977), 538-544, Bohlmann, F. et. al., Chem. Ber. (1970), 103, 561-563]. Furthermore, ingenol derivatives are known to degrade in the presence of acid [Appendino et. al., Eur. J. Org. Chem. (1999), 3413]. Also, ingenol-3-esters are readily rearranged to afford the ingenol-5-esters and ingenol-20-esters. This is particularly the case for esters of short-chain carboxylic acids [Sorg, B. et. al, Z. Naturforsch., (1982), 37B, 748-756]. The purification method previously described for the purification of ingenol-3-esters to avoid the rearranged side-products [Sorg, B. et. al, Z. Naturforsch., (1982), 37B, 748-756] is not suitable for large scale production of ingenol-3-angelate.



SUMMARY OF THE INVENTION

[0005] It is an object of this invention to provide a scalable process for the synthesis of ingenol-3-angelate (PEP005) starting from ingenol.

The present invention provides novel processes to produce ingenol-3-angelate from ingenol. The present disclosure further provides novel intermediates for the preparation of ingenol-3-angelate.



[0006] The invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II).

[0007] More specifically, the invention relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester) (I) from ingenol (II)





comprising the steps of:

1. (a) reacting one or both hydroxyl groups in positions 5 and 20 of ingenol with suitable hydroxyl protecting agents, same or different, to obtain a compound of the general formula (III) or (IV), i.e. protecting one or both hydroxyl groups in positions 5 and 20 of ingenol with a protective group to obtain a compound of the general formula (III) or (IV)



wherein R_1 represents hydrogen or a hydroxyl protective group and R_2 represents hydrogen or a hydroxyl protective group, or R_1 represents a hydroxyl protective group and R_2 represents hydrogen or a hydroxyl protective group, or wherein D represents a dihydroxyl protective group

2. (b) esterifying compounds (III) or (IV) to obtain compounds of the general formula (V) or (VI), i.e. esterifying the hydroxyl group at the 3-position of compounds (III) or (IV) to obtain compounds of the general formula (V) or (VI)





step (b) comprising reacting compound (III) or (IV) with:



1. (i) methyl angelate,
2. (ii) angeloyl chloride in the presence of a base, in a suitable solvent,
3. (iii) angelic acid anhydride, or
4. (iv) a mixed angelic acid anhydride;

wherein R_1 , R_2 and D are as described above, and

3. (c) removing the hydroxyl protective groups R_1 , or R_1 and R_2 , or D from compounds (V) or (VI) to obtain ingenol-3-angelate (I).


[0008] In another aspect, the disclosure relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-methanocyclopenta[a]cyclopropan[e]cyclodecen-6-yl ester) (I) from ingenol (II)





comprising the steps of:



(d) esterifying ingenol (II) to obtain a compound of the formula (VII)



wherein R_3 represents hydrogen or angeloyl, i.e. esterifying the 3- and the 20-hydroxyl group and optionally esterifying the 5-hydroxyl group of ingenol (II) to obtain a compound of the formula (VII) and

(e) cleaving the angelate ester(s) in position 20 or in position 5 and 20 of compound (VII) to obtain ingenol-3-angelate (I).

[0009] In a further aspect, the disclosure relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1*aR*,2*S*,5*R*,5*aS*,6*S*,8*aS*,9*R*,10*aR*)-5,5*a*-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1*a*,2,5,5*a*,6,9,10,10*a*-octahydro-1*H*-2,8*a*-methanocyclopenta[*a*]cyclopropa[*e*]cyclodecen-6-yl ester) (I) from ingenol (II)



comprising the step of:

(f) selective esterification of the 3-hydroxy group of compound (II) to obtain ingenol-3-angelate (I).

[0010] In another aspect, the disclosure relates to a compound of general structure (V) wherein R_1 represents hydrogen or a hydroxyl protective group and R_2 represents hydrogen or a hydroxyl protective group;

with the proviso that not both R_1 and R_2 represent hydrogen:

and with the proviso that R_1 and R_2 do not represent acetyl;

and with the proviso that R_1 and R_2 do not represent 2-[(2-aminobenzoyl)amino]benzoyl;

and with the proviso that R₁ does not represent decanoyl;

and with the proviso that R₁ does not represent 3-phenyl-2-propenoyl.

[0011] In another aspect the disclosure relates to a compound of general structure (VI) wherein D represents a dihydroxyl protective group; with the proviso that D does not represent isopropylidene.

[0012] In another aspect, the disclosure relates to a compound of general formula III wherein R₁ and R₂ independently represents hydrogen or an ether, acetal, ketal, silylether, or a sulfenate derived hydroxyl protective group;
with the proviso that not both R₁ and R₂ represent hydrogen;
and with the proviso that R₁ does not represent triphenylmethyl;
and with the proviso that R₁ does not represent t-butyldimethylsilyl.

[0013] In another aspect, the disclosure relates to a compound of general formula IV wherein D represents a dihydroxyl protective group;
with the proviso that D does not represent isopropylidene.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0014] All terms are intended to be understood as they would be understood by a person skilled in the art.

[0015] The term "hydroxyl protecting agent" is intended to mean a reagent which under suitable reaction conditions reacts with a hydroxyl group to form a hydroxyl protective group.

[0016] The term "hydroxyl protective group" is intended to include any group which forms a derivative of the hydroxyl group that is stable to the projected reactions wherein said hydroxyl protective group subsequently optionally can be selectively removed. Said hydroxyl derivative can be obtained by selective reaction of a hydroxyl protecting agent with a hydroxyl group.

[0017] The term "hydroxyl protecting group" is intended to have the same meaning as the term "hydroxyl protective group".

[0018] Ether derivatives, such as allyl ether, prenyl ether, *p*-methoxybenzyl ether, triphenylmethyl ether, 2-trimethylsilylethyl ether, *tert*-butyl ether, cinnamyl ether, propargyl

ether, *p*-methoxyphenyl ether, benzyl ether, 3,4-dimethoxybenzyl ether, 2,6-dimethoxybenzyl ether, *o*-nitrobenzyl ether, *p*-nitrobenzyl ether, 4-(trimethylsilylmethyl)-benzyl ether, 2-naphthylmethyl ether, diphenylmethyl ether, (4-methoxyphenyl)-phenylmethyl ether, (4-phenylphenyl)-phenylmethyl ether, *p,p'*-dinitrobenzhydryl ether, 5-dibenzosuberyl ether, tris(4-*tert*-butylphenyl)methyl ether, (α -naphthyl)-diphenylmethyl ether, *p*-methoxyphenyldiphenylmethyl ether, di(*p*-methoxyphenyl)phenylmethyl ether, tri(*p*-methoxyphenyl)methyl ether or 9-(9-phenyl)xanthenyl ether are examples of hydroxyl protecting groups.

[0019] Ether derived hydroxyl protective groups also include alkoxyalkylethers (acetals and ketals) such as 1-ethoxyethyl ether, 1-methyl-1-methoxyethyl ether, [(3,4-dimethoxybenzyl)oxy]methyl ether, guaiacolmethyl ether, 2-methoxyethoxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether, tetrahydropyranyl ether, tetrahydrofuranyl ether, methoxymethyl ether benzyloxymethyl ether, *p*-methoxybenzyloxymethyl ether, *p*-nitrobenzyloxymethyl ether, *o*-nitrobenzyloxymethyl ether, (4-methoxyphenoxy)methyl ether, *tert*-butoxymethyl ether, 4-pentenylloxymethyl ether, siloxymethyl ether, 1-methoxycyclohexyl ether, 4-methoxytetrahydropyranyl ether, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl ether, 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl ether, 1-(4-chlorophenyl)-4-methoxypiperidin-4-yl ether or 1-methyl-1-benzyloxyethyl ether.

[0020] Ether derived hydroxyl protective groups also include thioacetals and thio ketals such as tetrahydrothiopyranyl ether, 4-methoxytetrahydrothiopyranyl ether, tetrahydrothiofuranyl ether or 1,3-benzodithiolan-2-yl ether.

[0021] Hydroxyl protective groups also include silyl ether derivatives, such as trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, *tert*-butyldimethylsilyl ether, dimethylisopropylsilyl ether, diethylisopropylsilyl ether, diphenylmethylsilyl ether, triphenylsilyl ether, dimethylhexylsilyl ether, 2-norbornyldimethylsilyl ether, *tert*-butyldiphenylsilyl ether, (2-hydroxystyryl)dimethylsilyl ether, (2-hydroxystyryl)diisopropylsilyl ether, *tert*-butylmethoxyphenylsilyl ether or *tert*-butoxydiphenylsilyl ether.

[0022] Hydroxyl protective groups also include esters of hydroxyl groups such as acetate ester, chloroacetate ester, trifluoroacetate ester, phenoxyacetate ester, formate ester, benzoylformate ester, dichloroacetate ester, trichloroacetate ester, methoxyacetate ester, *p*-chlorophenoxyacetate ester, phenylacetate ester, 3-phenylpropionate ester, 4-pentenoate ester, 4-oxopentanoate ester, pivaloate ester, crotonate ester, 4-methoxycrotonate ester, angelate ester, benzoate ester or *p*-phenylbenzoate ester.

[0023] Hydroxyl protective groups also include carbonates of hydroxyl groups such as methoxymethyl carbonate, 9-fluorenylmethyl carbonate, methyl carbonate, ethyl carbonate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, vinyl carbonate, allyl carbonate or *p*-nitrophenyl carbonate.

[0024] Hydroxyl protective groups also include sulfenates of hydroxyl groups such as 2,4-dinitrophenylsulfenate.

[0025] A dihydroxyl protective group is any group which forms a derivative of a diol which is stable to the projected reactions wherein said dihydroxyl protective group subsequently optionally can be selectively removed. Said dihydroxyl derivative can be obtained by selective reaction of a dihydroxyl protecting agent with a diol.

[0026] Ketal derivatives, such as isopropylidene ketal (acetonide), cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzophenone ketal, 1-*tert*-butylethylidene ketal or 1-phenylethylidene ketal, 3-pentylidene ketal, 2,4-dimethyl-3-pentylidene ketal, 2,6-dimethyl-4-heptylidene ketal, 3,3-dimethyl-2-butylidene ketal; and acetal derivatives such as benzylidene acetal, 2,4-dimethoxybenzylidene acetal, 4-nitrobenzylidene acetal, 2,4,6-trimethylbenzylidene acetal, 2,2-dimethyl-1-propylidene acetal, methylene acetal, ethylidene acetal, *p*-methoxybenzylidene acetal, *tert*-butylmethylidene acetal, 3-(benzyloxy)propylidene acetal, acrolein acetal, 2-nitrobenzylidene acetal, mesitylene acetal or 2-naphthaldehyde acetal, are examples of dihydroxyl protective groups.

[0027] Other dihydroxyl protective groups include cyclic ortho esters or ortho esters, such as methoxymethylene acetal, ethoxymethylene acetal, 2-oxacyclopentylidene ortho ester or isopropoxymethylene acetal.

[0028] Other dihydroxyl protective groups include bisacetal derivatives such as butane 2,3-bisacetal or cyclohexane-1,2-diacetal; or dispiroketals such as octahydro-[2,2']-bipyranil ketal.

[0029] Other dihydroxyl protective groups include silyl derivatives such as di-*tert*-butylsilylene, dialkylsilylene, 1,3-(1,1,3,3-tetraisopropylidisiloxanylidene), 1,1,3,3-tetra-*tert*-butoxydisiloxanylidene, methylene-bis-(diisopropylsilanoxanylidene, or 1,1,4,4-tetraphenyl-1,4-disilanylidene derivatives.

[0030] Dihydroxyl protective groups also include cyclic carbonates.

[0031] Other dihydroxyl protective groups include cyclic boronates such as phenyl boronate, methyl boronate or ethyl boronate.

[0032] Hydroxyl protective groups and dihydroxyl protective groups also include solid phase supported protective groups. Solid phase supported reagents for the introduction of solid phase supported protective groups may include for example polymer-bound 2-Chlorotriptyl chloride for the introduction of a solid phase supported triptyl protective group, or Acetylpolystyrene resin or 4-(4-Hydroxyphenyl)butan-2-one-based resins for the preparation of solid phase supported ketal-protective groups.

[0033] Non-limiting examples of hydroxyl protective groups and dihydroxyl protective groups all included in the scope of this invention, can for example be found in "Protective Groups in Organic Synthesis", 4th ed. P.G.M. Wuts; T.W. Greene, John Wiley, 2007, page 16-366, and in P.J. Kocienski, "Protecting Groups", 3rd ed. G. Thieme, 2003.

[0034] Angelic acid is 2-methyl-2(*Z*)-butenoic acid.

[0035] Tiglic acid is 2-methyl-2(*E*)-butenoic acid.

[0036] The term "alkyl" is intended to indicate a radical obtained when one hydrogen atom is removed from a hydrocarbon. Said alkyl comprises 1-20, preferably 1-12, such as 1-6 carbon atoms. The term includes the subclasses normal alkyl (*n*-alkyl), secondary and tertiary alkyl, such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl and isopentyl.

[0037] The term "alkenyl" is intended to indicate a radical obtained when one hydrogen atom is removed from a hydrocarbon containing at least one C=C double bond. Said alkenyl comprises 3-12, preferably 3-6 carbon atoms, e.g. allyl.

[0038] The term alkyl halide is intended to indicate a molecule of the general formula R-X, wherein R is an optionally substituted alkyl group as defined above, and X is any halogen substituent such as chloro, bromo or iodo.

[0039] The term alkenyl halide is intended to indicate a molecule of the general formula R-X, wherein R is an optionally substituted alkenyl group as defined above, and X is any halogen substituent such as chloro, bromo or iodo. The term "alkoxy" is intended to indicate a radical of the formula -OR', wherein R' is alkyl as indicated above, e.g. methoxy, ethoxy, *n*-propoxy, isopropoxy, butoxy, etc.

[0040] The term "alkoxyalkyl" is intended to indicate an alkyl radical as defined above, which is substituted with an alkoxy radical as defined above, i.e. R'-O-R', wherein each R' is alkyl same or different, as indicated above, e.g. methoxymethyl, ethoxymethyl.

[0041] The term "alkoxyalkyl halide" is intended to indicate a molecule of the general formula R'-O-R'-X wherein each R' is alkyl, same or different, as indicated above, and X is any halogen substituent such as chloro, bromo or iodo, e.g. methoxymethyl chloride, ethoxymethyl chloride.

[0042] The term "alkylcarbonyl" is intended to indicate a radical of the formula -C(O)-R', wherein R' is alkyl as indicated above, e.g. acetyl.

[0043] The term "alkenylcarbonyl" is intended to indicate a radical of the formula -C(O)-R', wherein R' is alkenyl as indicated above, e.g. angeloyl.

[0044] The term "aryl" is intended to indicate a radical of the formula Ar-, obtained when one hydrogen atom is removed from a cyclic carbon containing compound with a delocalised $(4n+2)$ π -electron system. *n* is an integer >0, preferably 1 or 2. Examples of Ar- are phenyl, 2,4,6-trichlorophenyl, 4-nitrophenyl.

[0045] The term "arylalkyl" is intended to indicate a radical of the formula Ar-R'-, wherein Ar-

R"- is an alkyl radical as indicated above substituted with an aromatic radical, e.g. benzyl.

[0046] The term "acid halide" is intended to indicate a molecule of the general formula R'-C(O)-X or Ar-C(O)-X wherein R' is optionally substituted alkyl or alkenyl as defined above, Ar is optionally substituted aryl as defined above and X is halogen such as chloro, bromo or iodo, as defined herein. Examples of acid halides are acetyl chloride, chloroacetyl chloride, phenoxyacetyl chloride, benzoyl chloride, 2,4,6-trichlorobenzoyl chloride, 4-nitrobenzoyl chloride or angeloyl chloride.

[0047] The term "acid anhydride" is intended to indicate a molecule of the general formula R'-C(O)-O-C(O)-R' or Ar-C(O)-O-C(O)-Ar wherein R' is optionally substituted alkyl or alkenyl as defined above and Ar is optionally substituted aryl as defined above. Examples of acid anhydrides are acetic anhydride, angelic anhydride, benzoic anhydride or 2,4,6-trichlorobenzoic anhydride.

[0048] The term "mixed anhydride" is intended to indicate a molecule of the general formula R-C(O)-O-C(O)-R" or Ar-C(O)-O-C(O)-R' wherein R- and R'- are different and R' and R" are optionally substituted alkyl or alkenyl as defined above and Ar is optionally substituted aryl as defined above. Examples of "mixed anhydrides" are angeloyl 2,4,6-trichlorobenzoyl anhydride or angeloyl 4-nitrobenzoyl anhydride.

[0049] The term "alkoxycarbonyl" is intended to indicate a radical of the formula R'-O-C(O)-, wherein R' is alkyl as indicated above, e.g. methoxycarbonyl, ethoxycarbonyl, *n*-propoxycarbonyl, isopropoxycarbonyl, *tert*-butoxycarbonyl etc.

[0050] The term "arylsulfenyl" is intended to indicate a radical of the formula Ar-S(O)-wherein Ar- is as defined above, e.g. 2,4-dinitrophenylsulfenyl.

[0051] The term "diol" is intended to indicate a molecule containing two or more hydroxyl groups, in which the two hydroxyl groups are not attached to the same carbon atom. In general diol protecting groups are used for protection of 1,2-diols and/or 1,3-diols. Examples of "diols" are ingenol or ingenol-3-angelate.

[0052] The term "activated acid derivative" is intended to indicate a derivative of an acid, which under the chosen reaction conditions will react more readily than the corresponding acid with an alcohol to form an ester. Examples of "activated acid derivatives" are acid halides, acid anhydrides, "mixed anhydrides", methyl angelate or vinyl angelate.

[0053] The term "coupling reagent" is intended to indicate a reagent, which will facilitate the formation of an ester from an acid and an alcohol by the formal binding of water. Examples of "coupling reagents" are dicyclohexylcarbodiimide (DCC), 1-methyl-2-chloro-pyridinium iodide, HBTU (O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate), DMTMM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride), HATU (*N,N,N',N'*-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate), EDCI (*N*-(3-

Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride).

[0054] The term "activator" is intended to indicate a reagent, which will facilitate the formation of an ester from an acid or an activated acid derivative and an alcohol by the removal of acid from the reaction mixture. Examples of "activators" are triethylamine, *N,N*-diisopropylethylamine, pyridine or lutidine.

[0055] The term "catalyst" is intended to indicate a compound, which in substoichiometric or stoichiometric amount, or in excess, will accelerate the reaction without being consumed itself. Examples of a catalyst is DMAP (4-(*N,N*-dimethylamino)pyridine) or 1-hydroxybenzotriazole..

[0056] The term "enzymatic catalysis" is intended to indicate catalysis of chemical reactions by specialised proteins called enzymes. Examples of enzymes are lipases, esterases, proteases or cutinases.

[0057] The term "esterase" is intended to indicate an enzyme which is capable of catalysing the cleavage of an ester into acid and alcohol.

[0058] The term "lipase" is intended to indicate an enzyme which is capable of catalysing the hydrolysis of lipids. Lipases are often capable of hydrolysing esters that are not lipids. An example of a lipase is *Candida antarctica* Lipase B.

[0059] The term "angelate" is intended to indicate an ester of angelic acid.

[0060] The term "esterify" is intended to indicate a reaction in which a hydroxyl group is combined with a suitable reactant, i.e. combined with a carboxylic acid or a carboxylic acid derivative under suitable reaction conditions, to form an ester.

[0061] The term "ether derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of an ether group.

[0062] The term "ester derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of an ester group.

[0063] The term "acetal derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of an acetal group.

[0064] The term "ketal derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of a ketal group.

[0065] The term "silylether derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of a silylether group.

[0066] The term "sulfenate derived hydroxyl protective group" is intended to indicate a

hydroxyl protecting group in which the hydroxyl group to be protected is part of a sulfenate group.


[0067] The term "boronate derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of a boronate group.

[0068] The term "carbonate derived hydroxyl protective group" is intended to indicate a hydroxyl protecting group in which the hydroxyl group to be protected is part of a carbonate group.


Embodiments

[0069] The invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II), in which one or more hydroxyl groups are protected by hydroxyl protective groups or dihydroxyl protective groups, as further defined herein.

[0070] More specifically, the invention relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1a*R*,2*S*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1*H*-2,8a-methanocyclopenta[a]cyclopropano[e]cyclodecen-6-yl ester) (I) from ingenol (II)




(I)




(II)

comprising the steps of:

1. (a) protecting one or both hydroxyl groups in positions 5 and 20 of ingenol with a protective group to obtain a compound of the general formula (III) or (IV)



(III)




(IV)

wherein R_1 represents a hydroxyl protective group and R_2 represents hydrogen or a hydroxyl protective group, or wherein D represents a dihydroxyl protective group

2. (b) esterifying compounds (III) or (IV) to obtain compounds of the general formula (V) or (VI), step (b) comprising reacting compound (III) or (IV) with:
 1. (i) methyl angelate,
 2. (ii) angeloyl chloride in the presence of a base, in a suitable solvent,


3. (iii) angelic acid anhydride, or
4. (iv) a mixed angelic acid anhydride,



wherein R_1 , R_2 and D are as described above, and


3. (c) removing the hydroxyl protective groups R₁, or R₁ and R₂, or D from compounds (V) or (VI) to obtain ingenol-3-angelate (I).

[0071] In another embodiment the disclosure relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1*aR*,2*S*,5*R*,5*aS*,6*S*,8*aS*,9*R*,10*aR*)-5,5*a*-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1*a*,2,5,5*a*,6,9,10,10*a*-octahydro-1*H*-2,8*a*-methanocyclopenta[*a*]cyclopropa[*e*]cyclodecen-6-yl ester) (I) from ingenol (II)



comprising the steps of:

- (d) esterifying ingenol (II) to obtain a compound of the formula (VII)




wherein R₃ represents hydrogen or angeloyl, and

- (e) cleaving the angelate ester(s) in position 20 or in position 5 and 20 of compound (VII) to obtain ingenol-3-angelate (I).

[0072] In another embodiment the disclosure relates to a method of producing ingenol-3-angelate (2-Methyl-2(Z)-butenoic acid (1*a**R*,2*S*,5*R*,5*aS*,6*S*,8*aS*,9*R*,10*aR*)-5,5*a*-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1*a*,2,5,5*a*,6,9,10,10*a*-octahydro-1*H*-2,8*a*-

methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester) (I) from ingenol (II)



comprising the step of:

(f) selective esterification of the 3-hydroxy group of compound (II) to obtain ingenol-3-angelate (I).

[0073] In one embodiment, R_1 may represent hydrogen or R_1 may represent an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group and R_2 may represent hydrogen or an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group.

[0074] For example, R_1 may be selected from the group consisting of hydrogen, [(3,4-dimethoxybenzyl)oxy]methyl, guaiacolmethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, allyl, prenyl, *p*-methoxybenzyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl, triethylsilyl, triisopropylsilyl, *tert*-butyldimethylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, *tert*-butyldiphenylsilyl, triphenylsilyl, acetyl, chloroacetyl, phenoxyacetyl or angeloyl.

[0075] R_2 may for instance be selected from the group consisting of hydrogen or [(3,4-dimethoxybenzyl)oxy]methyl, guaiacolmethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, allyl, prenyl, *p*-methoxybenzyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl, triethylsilyl, triisopropylsilyl, *tert*-butyldimethylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, *tert*-butyldiphenylsilyl, triphenylsilyl, acetyl, chloroacetyl, phenoxyacetyl or angeloyl.

[0076] In another embodiment, D may represent an acetal, ketal, diacetal, diketal, ortho ester, silyl, boronate or a carbonate derived dihydroxyl protective group. For example, D may be selected from the group consisting of isopropylidene, cyclopentylidene, cyclohexylidene, *p*-methoxybenzylidene, methoxymethylene, 2-oxacyclopentylidene, 2,3-dimethoxybutane-2,3-diyl, 1,2-dimethoxycyclohexan-1,2-di-yl, octahydro-[2,2']-bipyran-2,2'-di-yl, di-*tert*-butylsilylene, 1,3-(1,1,3,3-tetraisopropylidisiloxanylidene), phenyl boronate, 3-pentylidene, 2,4-dimethyl-3-pentylidene, 2,6-dimethyl-4-heptylidene, 3,3-dimethyl-2-butyldiene, 1-phenyl-1-ethylidene, benzylidene, 2,4-dimethoxybenzylidene, 4-nitrobenzylidene, 2,4,6-trimethylbenzylidene, 2,2-dimethyl-1-propylidene, ethoxymethylene or isopropoxymethylene..

[0077] In a specific embodiment, R_1 represents a hydroxyl protective group, and R_2 represents hydrogen.

[0078] In another specific embodiment, R₃ represents hydrogen.

[0079] In another embodiment the disclosure relates to a method wherein step (b) comprises reacting compound (III) or (IV), wherein R₁, R₂ and D are as defined above with angelic acid in the presence of an enzyme.

[0080] In another embodiment the disclosure relates to a method wherein step (b) comprises reacting compound (III) or (IV), wherein R₁, R₂ and D are as defined above with angelic acid in the presence of a coupling reagent.

[0081] In an embodiment the coupling reagent is selected from the group consisting of DCC, HATU, EDCI or 2-chloro-1-methyl-pyridinium iodide.

[0082] The invention relates to a method wherein step (b) comprises reacting compound (III) or (IV), wherein R₁, R₂ and D are as defined above, with an activated derivative of angelic acid, as further defined herein.

[0083] In an embodiment the activated derivative of angelic acid is selected from the group consisting of methyl angelate, angeloyl chloride (in the presence of a base in a suitable solvent), angelic acid anhydride, [(Z)-2-methylbut-2-enoyl] 2,4,6-trichlorobenzoate or angeloyl 4-nitrobenzoyl anhydride.

[0084] In another embodiment the invention relates to a method wherein step (b) comprises reacting compound (III) or (IV), wherein R₁, R₂ and D are as defined above, with angeloyl chloride (in the presence of a base in a suitable solvent) or with angelic acid anhydride or with a mixed angelic acid anhydride.

[0085] In an embodiment of the invention, step (b) comprises reacting compound (III) or (IV) with an angelic acid halide which is angeloyl chloride, in the presence of a base in a suitable solvent.

[0086] In an embodiment of the invention, step (b) comprises reacting compound (III) or (IV) with a mixed angelic anhydride which is [(Z)-2-methylbut-2-enoyl] 2,4,6-trichlorobenzoate or angeloyl 4-nitrobenzoyl anhydride.

[0087] In an embodiment the disclosure relates to a compound of general formula (V) wherein R₁ represents hydrogen or an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group, and R₂ represents hydrogen or an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group.

[0088] In an embodiment the disclosure relates to a compound of general formula (V) wherein R₁ and R₂ independently represents hydrogen or [(3,4-dimethoxybenzyl)oxy]methyl, guaiacolmethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl,

1-methyl-1-methoxyethyl, allyl, prenyl, *p*-methoxybenzyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl, triethylsilyl, triisopropylsilyl, *tert*-butyldimethylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, *tert*-butyldiphenylsilyl, triphenylsilyl, chloroacetyl or phenoxyacetyl.

[0089] In an embodiment the disclosure relates to a compound of general formula (V) wherein R₁ represents a hydroxyl protective group and R₂ represents hydrogen; In an embodiment the disclosure relates to a compound chosen from the group consisting of Ingenol-20-(*tert*-butyldimethylsilyl)-ether-3-angelate.

[0090] In an embodiment the disclosure relates to a compound of general formula (VI) wherein D represents an acetal, ketal, diacetal, diketal, ortho ester, silyl, boronate or a carbonate dihydroxyl protective group.

[0091] In an embodiment the disclosure relates to a compound of general formula (VI) wherein D represents cyclopentylidene, cyclohexylidene, *p*-methoxybenzylidene, methoxymethylene, 2-oxacyclopentylidene, 2,3-dimethoxybutane-2,3-di-yl, 1,2-dimethoxycyclohexan-1,2-di-yl, octahydro-[2,2']-bipyran-2,2'-di-yl, di-*tert*-butylsilylene, 1,3-(1,1,3,3-tetraisopropylidisiloxanylidene), phenyl boronate, 3-pentylidene, 2,4-dimethyl-3-pentylidene, 2,6-dimethyl-4-heptylidene, 3,3-dimethyl-2-butyldiene, 1-phenyl-1-ethylidene, benzylidene, 2,4-dimethoxybenzylidene, 4-nitrobenzylidene, 2,4,6-trimethylbenzylidene, 2,2-dimethyl-1-propylidene, ethoxymethylene or isopropoxymethylene.

[0092] In an embodiment the disclosure relates to a compound chosen from the group consisting of
ingenol-5,20-(di(*tert*-butyl)silylene)-ether-3-angelate

[0093] In an embodiment the disclosure relates to a compound of general formula (IV) wherein D represents an acetal, ketal, diacetal, diketal, ortho ester, silyl, boronate or a carbonate derived dihydroxyl protective group.

[0094] In an embodiment the disclosure relates to a compound of general formula (IV) wherein D represents cyclopentylidene, cyclohexylidene, *p*-methoxybenzylidene, methoxymethylene, 2-oxacyclopentylidene, 2,3-dimethoxybutane-2,3-di-yl, 1,2-dimethoxycyclohexan-1,2-di-yl, octahydro-[2,2']-bipyran-2,2'-di-yl, di-*tert*-butylsilylene, 1,3-(1,1,3,3-tetraisopropylidisiloxanylidene), phenyl boronate, 3-pentylidene, 2,4-dimethyl-3-pentylidene, 2,6-dimethyl-4-heptylidene, 3,3-dimethyl-2-butyldiene, 1-phenyl-1-ethylidene, benzylidene, 2,4-dimethoxybenzylidene, 4-nitrobenzylidene, 2,4,6-trimethylbenzylidene, 2,2-dimethyl-1-propylidene, ethoxymethylene or isopropoxymethylene.

[0095] In an embodiment the disclosure relates to a compound chosen from the group consisting of

Ingenol-5,20-(3-pentylidene)-ketal,
Ingenol-5,20-(2,4-dimethyl-3-pentylidene)-ketal,

Ingenol-5,20-(2,6-dimethyl-4-heptylidene)-ketal,
 Ingenol-5,20-cyclopentylidene-ketal,
 Ingenol-5,20-cyclohexylidene-ketal,
 Ingenol-5,20-(3,3-dimethyl-2-butyldiene)-ketal,
 Ingenol-5,20-(1-phenyl-1-ethylidene)-ketal,
 Ingenol-5,20-benzylidene-acetal,
 Ingenol-5,20-(4-methoxybenzylidene)-acetal,
 Ingenol-5,20-(2,4-dimethoxybenzylidene)-acetal,
 Ingenol-5,20-(4-nitrobenzylidene)-acetal,
 Ingenol-5,20-(2,4,6-trimethylbenzylidene)-acetal,
 Ingenol-5,20-(2,2-dimethyl-1-propylidene)-acetal,
 Ingenol-5,20-methyl-orthoformate,
 Ingenol-5,20-ethyl-orthoformate,
 Ingenol-5,20-(prop-2-yl)-orthoformate, or
 Ingenol-5,20-(di(*tert*-butyl)silylene)-ether.

[0096] In an embodiment the disclosure relates to a compound of general structure (VII) wherein R_3 represents hydrogen or angeloyl.

[0097] In an embodiment the invention relates to the use of a compound of general formula (III), (IV), (V) or (VI) as an intermediate in the manufacture of ingenol-3-angelate defined herein.

Synthetic Methods

[0098] The compounds of the general formula (III) and (IV) can for example be synthesised by reacting compound (II) with a hydroxyl protecting agent or a dihydroxyl protecting agent according to methods well known to a person skilled in the art, such as methods described in "Protective Groups in Organic Synthesis", 4th ed. P.G.M. Wuts; T.W. Greene, John Wiley, 2007 or in P.J. Kocienski, "Protecting Groups", 3rd ed. G. Thieme, 2003 and references cited therein.

[0099] For example, compound (III) wherein R_1 is triphenylmethyl and R_2 is hydrogen or triphenylmethyl, can be synthesised by reacting compound (II) with a triphenylmethyl reagent such as triphenylmethylpyridinium fluoroborate or triphenylmethyl chloride in a suitable solvent such as pyridine, *N,N*-dimethylformamide or dichloromethane in the presence or in the absence of base [eg. Opferkuch et.al., Z. Naturforschung, (1981), 36B, 878].

[0100] Compound (III) wherein R_1 is arylalkyl or alkenyl such as *p*-methoxybenzyl or allyl and R_2 is hydrogen or arylalkyl or alkenyl, can for example be synthesised by reacting compound (II) with an alkyl halide or alkenyl halide such as *p*-methoxybenzyl halide or allyl halide in a suitable solvent such as *N,N*-dimethylformamide or tetrahydrofuran optionally in the presence

of a suitable base such as potassium carbonate.

[0101] Compound (III) wherein R_1 is alkoxyalkyl such as methoxymethyl or 2-methoxyethoxymethyl and R_2 is hydrogen or alkoxyalkyl such as methoxymethyl or 2-methoxyethoxymethyl, can for example be synthesised by reacting compound (II) with an alkoxyalkyl halide such as methoxymethyl chloride or 2-methoxyethoxymethyl chloride in a suitable solvent such as tetrahydrofuran or dichloromethane optionally in the presence of a suitable base such as *N,N*-diisopropylethylamine.

[0102] Compound (III) wherein R_1 is 2-tetrahydropyranyl and R_2 is hydrogen or 2-tetrahydropyranyl, can for example be synthesised by reacting compound (II) with dihydropyran in a suitable solvent such as dichloromethane or acetonitrile in the presence of a suitable acid such as *p*-toluenesulfonic acid.

[0103] Compound (III) wherein R_1 is silyl and R_2 is hydrogen or silyl, can for example be synthesised by reacting compound (II) with a silyl chloride such as *tert*-butyldimethylsilyl chloride, *tert*-butyldiphenylsilyl chloride or triisopropylsilyl chloride in a suitable solvent such as *N,N*-dimethylformamide, pyridine, dichloromethane, tetrahydrofuran or acetonitrile optionally in the presence of a suitable base such as imidazole, triethylamine, *N,N*-diisopropylethylamine, 4-(*N,N*-dimethylamino)pyridine or 2,6-lutidine, or by reacting compound (II) with a silyl triflate such as *tert*-butyldimethylsilyl trifluoromethanesulfonate in a suitable solvent such as dichloromethane optionally in the presence of a suitable base such as triethylamine.

[0104] Compound (III) wherein R_1 is alkylcarbonyl or alkenylcarbonyl such as acetyl, chloroacetyl or phenoxyacetyl or angeloyl and R_2 is hydrogen or alkylcarbonyl or alkenylcarbonyl, can for example be synthesised by reacting compound (II) with the corresponding acid chloride such as acetyl chloride, chloroacetyl chloride or phenoxyacetyl chloride or angeloyl chloride or by reacting compound (II) with an acid anhydride such as acetic anhydride, chloroacetic anhydride or phenoxyacetic anhydride or angelic acid anhydride in a suitable solvent such as pyridine or dichloromethane optionally in the presence of a suitable base such as *N,N*-diisopropylethylamine or 4-(*N,N*-dimethylamino)pyridine, or by reacting compound (II) with an acyl donor such as vinyl acetate or chloroacetic anhydride or vinyl angelate optionally in the presence of an enzyme as catalyst.

[0105] Compound (III) wherein R_1 is alkoxycarbonyl such as methoxycarbonyl or 9-fluorenylmethoxy carbonyl and R_2 is hydrogen or alkoxycarbonyl such as methoxycarbonyl or 9-fluorenylmethoxy carbonyl, can for example be synthesised by reacting compound (II) with the corresponding alkylchloro formate in a suitable solvent such as pyridine or dichloromethane optionally in the presence of a suitable base such as triethylamine or *N,N,N',N'*-tetramethylethylenediamine.

[0106] Compound (III) wherein R_1 is an arylsulfenyl such as 2,4-dinitrophenylsulfenyl and R_2 is hydrogen or an arylsulfenyl such as 2,4-dinitrophenylsulfenyl can for example be synthesised

by reacting compound (II) with an optionally substituted sulfonylchloride such as 2,4-dinitrophenylsulfonyl chloride in a suitable solvent such as dichloromethane optionally in the presence of a suitable base such as pyridine.

[0107] Compound (IV) wherein D represents an acetal such as benzylidene acetal can for example be synthesised by reacting compound (II) with an aldehyde such as benzaldehyde or a dimethoxy acetal such as benzaldehyde dimethyl acetal in a suitable solvent such as dichloromethane or *N,N*-dimethylformamide or THF in the presence of a suitable acid such as *p*-toluenesulfonic acid; or a benzylidene acetal can for example be prepared by reacting compound (II) with an α,α -di-halo-toluene derivative such as for example α,α -dibromotoluene or α,α -(bispyridinium)toluenedibromide in a suitable solvent such as pyridine, DMF or THF in the presence of a suitable base such as K_2CO_3 or LiHMDS.

[0108] Compound (IV) wherein D represents a ketal such as isopropylidene ketal can for example be synthesised by reacting compound (II) with a ketone such as acetone or a dimethoxy ketal such as 2,2-dimethoxy propane in a suitable solvent such as dichloromethane or *N,N*-dimethylformamide or THF in the presence of a suitable acid such as *p*-toluenesulfonic acid or methanesulfonic acid. Acetone and 2,2-dimethoxy propane can also act as solvents.

[0109] Compound (IV) wherein D represents a bis-acetal such as butane 2,3-bisacetal or cyclohexane-1,2-diacetal or a dispiroketal such as octahydro-[2,2']-bipyranil ketal can be prepared by reacting compound (II) with 2,2,3,3-tetramethoxybutane or cyclohexane-1,2-dione and trimethyl orthoformate in the presence of a suitable acid such as *p*-toluenesulfonic acid in a suitable solvent such as methanol or by reacting with bisdihydropyran in the presence of a suitable acid such as *p*-toluenesulfonic acid in a suitable solvent such as dichloromethane.

[0110] Compound (IV) wherein D represents a cyclic ortho ester such as methoxymethylene acetal or 2-oxacyclopentylidene ortho ester can for example be synthesised by reacting compound II with an ortho ester such as trimethyl orthoformate in a suitable solvent such as dichloromethane in the presence of an acid such as *p*-toluenesulfonic acid; or by reacting compound II with a dihalomethylalkoxyether, such as for example dichloromethyl methyl ether, in a suitable solvent such as DMF or THF in the presence of a suitable base such as LiHMDS or K_2CO_3 .

[0111] Compound (IV) wherein D represents silyl such as di-*tert*-butylsilylene can for example be synthesised by reacting compound II with a dialkylsilyl dichloride or a dialkylsilyl ditriflate such as di-*tert*-butylsilyl ditriflate in a solvent such as acetonitrile, dichloromethane or *N,N*-dimethylformamide optionally in the presence of a base such as triethylamine or 2,6-lutidine.

[0112] Compound (IV) wherein D represents carbonyl can for example be synthesised by reacting compound (II) with phosgene or *N,N'*-carbonyldiimidazole in pyridine.

[0113] Compound (IV) wherein D represents a boronate such as phenyl boronate can for example be synthesised by reacting compound (II) with phenylboronic acid in pyridine.

[0114] The synthesis of compounds of general formula (III) and (IV) from compound (II) may be performed both in a batch reactor and in a flow reactor, such as for example an Alfa Laval ART® Plate Reactor 37

[0115] The reagents for introducing the hydroxyl protective groups R1, R2 or D may be solid phase supported reagents such as for example polymer bound 2-Chlorotriptyl chloride, acetyl polystyrene resin or 4-(4-Hydroxyphenyl)butan-2-one-based resins.

[0116] The compounds of the general formula (III) and (IV) can be esterified in the 3-position to obtain the compounds of the general formula (V) and (VI) by reaction of compound (III) or (IV) with activated angelic acid derivatives as further defined herein. In an embodiment of the disclosure, compound (II) can be esterified to obtain compounds of the general formula (VII) by reaction of compound (II) with angelic acid in the presence of a coupling reagent or with activated angelic acid derivatives. The compounds may be prepared according to, but not limited to, methods for esterification described in "Esterification" by J. Otera, Wiley-VCH, 2003 and references cited therein.

[0117] For example compound (V), (VI) or (VII) can be synthesised by reacting compound (III), (IV) or (II) with an activated angelic acid derivative such as the angeloyl halide angeloyl chloride (in the presence of a base, in a suitable solvent). The esterification by reaction with angeloyl chloride takes place in the presence of a base such as pyridine or triethylamine, LiHMDS or DMAP, in a suitable solvent such as for example pyridine or THF. Examples of the synthesis of angelic acid esters using angeloyl chloride can for example be found in Beeby, P.J., Tetrahedron Lett., (1977), 38, 3379-3382.

[0118] Compound (V) or (VI) can for example be synthesised by reacting compound (III) or (IV) with an activated angelic acid derivative such as angelic anhydride. The esterification by reaction with angelic anhydride can take place without a catalyst, or in the presence of an acidic catalyst using an acid such as perchloric acid or a Lewis acid such as scandium (III) triflate or bismuth (III) triflate, or in the presence of a base such as sodium hydrogencarbonate or triethylamine, LiHMDS, NaHMDS, KHMDS, pyridine, cesium carbonate or DMAP, in a suitable solvent such as for example THF, MeCN, pyridine or MTBE. Examples of the synthesis of angelic acid esters using angelic acid anhydride can for example be found in Hartmann, B. et. al.; Tetrahedron Lett., (1991), 32, 5077-5080 or in JP2008127287.

[0119] Compound (V) or (VI) can for example be synthesised by reacting compound (III) or (IV) with an activated angelic acid derivative such as a mixed anhydride such as angeloyl trichlorobenzoyl anhydride, such as angeloyl 2,4,6-trichlorobenzoyl anhydride. The esterification by reaction with a mixed anhydride can take place without a catalyst, or in the presence of an acidic catalyst using an acid such as perchloric acid or a Lewis acid such as scandium (III) triflate or bismuth (III) triflate, or in the presence of a base such as sodium hydrogencarbonate or triethylamine, in a suitable solvent such as for example toluene. Examples of the synthesis of angelic acid esters using angeloyl trichlorobenzoyl anhydride can

for example be found in Hartmann, B. et. al.; Tetrahedron Lett. (1991), 32, 5077-5080, or in Ball, B., Org. Lett., (2007), 9, 663-666.

[0120] In methods of the disclosure, compound (V) or (VI) can be synthesised by reacting compound (III) or (IV) with angelic acid in the presence a coupling reagent. Angelic acid can be esterified in the presence of a coupling reagent such as a carbodiimide such as dicyclohexylcarbodiimide or EDCI (*N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride) with or without catalysts such as 1-hydroxybenzotriazole. Examples of the synthesis of angelic acid esters using dicyclohexylcarbodiimide with or without catalysts can for example be found in Hoskins, W.M., J. Chem. Soc. Perkin Trans. 1, (1977), 538-544. Other coupling reagents for esterification can for example be 2-halo-1-alkylpyridinium salts such as 1-methyl-2-chloro-pyridinium iodide, or hydroxy-benzotriazol derivatives such as HBTU (*O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate), or HATU (*N,N,N',N'*-Tetramethyl-*O*-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate), or triazine derivatives such as DMTMM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride. Suitable solvents can be methylene chloride, toluene, DMF or THF. Solid-supported coupling reagents can also be used in the esterification step [Nam, N.-H., Journal of Combinatorial Chemistry, (2003), 5, 479-545, or "Esterification" by J. Otera, Wiley-VCH, 2003].

[0121] In methods of the disclosure, Compound (V), (VI), (VII) or (I) can for example be synthesised by reacting compound (III), (IV) or (II) with an angeloyl donor such as angelic acid ester such as vinyl angelate or angelic acid thioester in the presence of an enzyme such as a lipase or an esterase. Examples of esterification of an ingenol derivative catalysed by lipase can be found in Teng, R.W., Fitoterapia, (2009), 80, 233-236.

[0122] The synthesis of compounds of general formula (V) and (VI) from compound of general formula (III) and (IV) may be performed both in a batch reactor and in a flow reactor.

[0123] The reagents for the synthesis of compounds of general formula (V) and (VI) from compound of general formula (III) and (IV) may be solid phase supported reagents.

[0124] Ingenol-3-angelate (I) can be synthesised by selective removal of the protective groups, R₁ and R₂ or D, from the compounds of the general structure V or VI, according to methods well known to a person skilled in the art for deprotection of hydroxyl or dihydroxyl protective groups, such as methods described in "Protective Groups in Organic Synthesis", 4th ed. P.G.M. Wuts; T.W. Greene, John Wiley, 2007 or in P.J. Kocienski, "Protecting Groups", 3rd ed. G. Thieme, 2003 and references cited therein.

[0125] In methods disclosed herein, ingenol-3-angelate (I) can be synthesised by selective removal of the angeloyl groups from the 20-position or from the 5- and the 20-positions of the compound of the general structure (VII).

[0126] For example compound (I) can be synthesised from compound (V) wherein R₁ represents hydrogen or alkyl such as triphenylmethyl and R₂ represents hydrogen or

triphenylmethyl by reacting compound (V) with a suitable acid such as formic acid or trifluoroacetic acid in a suitable solvent such as ether, methanol or dichloromethane.

[0127] Compound (I) can for example be synthesised from compound (V) wherein R_1 represents hydrogen or alkyl such as *p*-methoxybenzylmethyl or allyl and R_2 represents hydrogen or *p*-methoxybenzylmethyl or allyl by reacting compound (V) with 2,5-dichloro-5,6-dicyano-*p*-benzoquinone (DDQ) in dichloromethane. The allyl group can also be removed by isomerisation of the olefin to a vinyl ether by reaction with a transition metal catalyst such as Wilkinson's catalyst (Rhodium(I) tris(triphenylphosphine) chloride), followed by cleavage of the vinyl ether in the presence of water.

[0128] Compound (I) can for example be synthesised from compound (V) wherein R_1 represents hydrogen or alkoxyalkyl such as 2-methoxyethoxymethyl and R_2 represents hydrogen or alkoxyalkyl such as 2-methoxyethoxymethyl by cleaving the acetal moiety of R_1 and/or R_2 , for example by acid catalysed cleavage with a Lewis acid such as zinc (II) bromide or titanium (IV) chloride in a suitable solvent such as dichloromethane.

[0129] Compound (I) can for example be synthesised from compound (V) wherein R_1 represents hydrogen or alkoxyalkyl such as 2-tetrahydropyranyl and R_2 represents hydrogen or alkoxyalkyl such as 2-tetrahydropyranyl by cleaving the acetal moiety of R_1 and/or R_2 , for example by acid catalysed cleavage in the presence of a suitable acid such as *p*-toluenesulfonic acid in a suitable solvent such as methanol.

[0130] Compound (I) can for example be synthesised from compound (V) wherein R_1 represents hydrogen or silyl such as *tert*-butyldimethylsilyl and R_2 represents hydrogen or silyl such as *tert*-butyldimethylsilyl by reacting compound (V) with a suitable acid such as hydrogen chloride in a suitable solvent such as methanol or by reacting with a fluoride source such as tetra *n*-butylammonium fluoride or tetrafluorosilane in a suitable solvent such as tetrahydrofuran or acetonitrile.

[0131] Compound (I) can for example be synthesised from compound (V) wherein R_1 represents hydrogen or alkylcarbonyl such as acetyl or chloroacetyl and R_2 represents hydrogen or alkylcarbonyl such as acetyl or chloroacetyl by hydrolysing the ester moiety of R_1 and/or R_2 by enzymatic catalysis utilising an enzyme such as a lipase, or by hydrolysing the ester moiety of R_1 and/or R_2 in a suitable solvent such as methanol or water in the presence of a suitable base such as potassium carbonate or in the presence of a suitable acid such as hydrogen chloride.

[0132] Compound (I) can for example be synthesised from compound V wherein R_1 represents hydrogen or alkoxy carbonyl such as 9-fluorenylmethoxycarbonyl and R_2 represents hydrogen or alkoxy carbonyl such as 9-fluorenylmethoxycarbonyl by cleaving the carbonate

moiety of R₁ and/or R₂ by cleavage in the presence of a suitable base such as triethylamine in a suitable solvent such as pyridine. Compound (I) can for example be synthesised from compound (V) wherein R₁ represents hydrogen or 2,4-dinitrophenylsulfenyl and R₂ represents hydrogen or 2,4-dinitrophenylsulfenyl by cleavage of the sulfenate moiety of R₁ and/or R₂ with a nucleophile such as sodium cyanide in a suitable solvent such as methanol.

[0133] Compound (I) can for example be synthesised from compound (VI) wherein D represents an acetal such as benzylidene acetal by cleaving the acetal moiety in the presence of a suitable acid such as acetic acid, trifluoroacetic acid or p-toluenesulfonic acid in a suitable solvent such as water, dichloromethane or methanol.

[0134] Compound (I) can for example be synthesised from compound (VI) wherein D represents a ketal such as isopropylidene ketal by cleaving the ketal moiety in the presence of a suitable acid such as aqueous hydrogen chloride, acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, solid supported p-toluenesulfonic acid, methanesulfonic acid, phosphoric acid or formic acid, in a suitable solvent such as methanol, THF or isopropanol.

[0135] Compound (I) can for example be synthesised from compound (VI) wherein D represents a cyclic ortho ester such as methoxymethylene acetal by cleaving the orthoester moiety in the presence of a suitable acid such as aqueous hydrogen chloride or acetic acid in a suitable solvent such as dioxan or water.

[0136] Compound (I) can for example be synthesised from compound (VI) wherein D represents silyl such as di-*tert*-butylsilylene by reacting compound (VI) with fluoride source such as tetra *n*-butylammonium fluoride or tetrafluorosilane in a suitable solvent such as tetrahydrofuran or acetonitrile.

[0137] Compound (I) can for example be synthesised from compound (VI) wherein D represents carbonyl by cleaving the carbonate moiety in the presence of a suitable base such as pyridine in a suitable solvent such as water or by enzymatic catalysed hydrolysis in the presence of an enzyme such as a lipase or an esterase.

[0138] Compound (I) can for example be synthesised from compound (VI) wherein D represents a boronate such as phenyl boronate by transesterification with a diol such as 1,3-propanediol.

[0139] The synthesis of compound (I) from compounds of general formula (V) and (VI) may be performed both in a batch reactor and in a flow reactor.
The reagents for the synthesis of compound (I) from compound of general formula (V) and (VI) may be solid phase supported reagents.

[0140] In methods disclosed herein, compound (I) can for example be synthesised from compound (VII) wherein R₃ represents angeloyl or hydrogen by enzymatic catalysed hydrolysis

of the ester moiety in the 20-position or in the 5- and 20-positions in the presence of an enzyme such as a lipase or an esterase.

[0141] In a still further aspect, the present disclosure relates to a compound of general structure (V), wherein R_1 represents a hydroxyl protective group and R_2 represents hydrogen or a hydroxyl protective group, or a compound of general structure (VI), wherein D represents a dihydroxyl protective group, or a compound of general structure (VII), wherein R_3 represents hydrogen or angeloyl.

EXAMPLES

General

[0142] All the starting materials used are commercially available, unless otherwise described. For proton nuclear magnetic resonance (^1H NMR) spectra, chemical shift values (δ) (in ppm) are quoted relative to the internal standard tetramethylsilane ($\delta = 0.00$). The value of a multiplet, either defined doublet (d), triplet (t), quartet (q) or a range (m) is given. All organic solvents used were anhydrous, unless otherwise specified.

[0143] Flash chromatography was performed on silica gel. Appropriate mixtures of ethyl acetate, dichloromethane, methanol, petroleum ether (bp. 40-60 °C), and heptane were used as eluents unless otherwise noted.

Abbreviations

[0144]

Bu_3N : Tributylamine

CDI: 1,1'-Carbonyldiimidazole

Cs_2CO_3 : Cesium carbonate

DCC: *N,N'*-Dicyclohexylcarbodiimide

DIPEA: *N,N*-Diisopropylethylamine

DMAP: 4-(Dimethylamino)pyridine

EDCI: *N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride

HATU: *N,N,N',N'*-Tetramethyl-*O*-(7-azabenzotriazol-1-yl)uranium hexafluorophosphate

HCl: Hydrochloric acid

HOAt: 3*H*-[1,2,3]-Triazolo[4,5-*b*]pyridin-3-ol

K₂CO₃: Potassium carbonate

KHMDS: Potassium hexamethyldisilazide

LiHMDS: Lithium hexamethyldisilazide

MSA: Methanesulfonic acid

NaHMDS: Sodium hexamethyldisilazide

TEA: Triethylamine

CDCl₃: Deuteriochloroform

DCM: Dichloromethane

DMF: *N,N*-Dimethylformamide

IPA: 2-Propanol (isopropyl alcohol)

MeCN: Acetonitrile

MeTHF: 2-Methyltetrahydrofuran

MTBE: Methyl *tert*-butyl ether

PhMe: Toluene

TFA: Trifluoroacetic acid

THF: Tetrahydrofuran

I: Ingenol

I-3-Ang: Ingenol-3-angelate

I-3-Tig: Ingenol-3-tiglate

I-3,4-A: Ingenol-3,4-acetonide

I-5,20-A: Ingenol-5,20-acetonide

I-3,4:5,20-A: Ingenol-3,4:5,20-diacetonide

I-5,20-A-3-Ang: Ingenol-5,20-acetonide-3-angelate

I-5,20-A-3-Tig: Ingenol-5,20-acetonide-3-tiglate

I-3,4-X: Ingenol-3,4-acetal/ketal

I-5,20-X: Ingenol-5,20-acetal/ketal

I-3,4:5,20-X: Ingenol-3,4:5,20-diacetal/diketal

AngOH: Angelic acid

Ang₂O: Angelic anhydride

AngOMe: Methyl angelate

AngCl: Angeloyl chloride

AngIm: Angeloyl imidazolidine

AngOAt: Angeloyl HOAt ester

AngOTig: Angeloyl tiglate

TigOH: Tiglic acid

Tig₂O: Tiglic anhydride

TigOMe: Methyl tiglate


TigCl: Tigloyl chloride

¹H NMR: Proton nuclear magnetic resonance

TLC: Thin layer chromatography

Equiv.: Equivalents

N/A: Not applicable



Preparation of ingenol-5,20-acetonide (Compound 1)

Example 1

[0145] Ingenol (1.00 g, 2.30 mmol) was dissolved in a solution of *p*-toluenesulphonic acid monohydrate in acetone (0.47 mg/mL, 22.5 mL). The solution was stirred at room temperature for 25 min. To this solution was added saturated aqueous solution of sodium hydrogencarbonate (0.2 mL). The obtained mixture was concentrated in vacuo. The residue was taken up in brine and extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 19:1 → heptane/ethyl acetate 0:1), giving the title compound as a white solid (616 mg, 69%).

Also see: Opferkuch, H. J. et al., Z. Naturforsch. 1981, 36b, 878-887
(compound **4**)

¹H NMR (300 MHz, CDCl₃) δ 5.91 (q, J = 1.5 Hz, 1H), 5.82-5.77 (m, 1H), 4.25 (d, J = 4.5 Hz, 1H), 4.20 - 4.07 (m, 3H), 3.93 (s, 1H), 3.51 (s, 1H), 2.57 - 2.41 (m, 2H), 2.25 (ddd, J = 15.7, 8.4, 2.9 Hz, 1H), 1.85 (d, J = 1.5 Hz, 3H), 1.77 (dt, J = 15.8, 5.9 Hz, 1H), 1.41 (s, 3H), 1.35 (s, 3H), 1.13 (s, 3H), 1.05 (s, 3H), 1.00 - 0.87 (m, 4H), 0.70 (td, J = 8.4, 6.4 Hz, 1H).


Example 2

[0146] Ingenol (7.0 g, 20.1 mmol) was dissolved in a solution of *p*-toluenesulfonic acid monohydrate in acetone (0.2 mg/mL, 200 mL). The solution was stirred at room temperature for 1.5 h (TLC control). To this solution was added saturated aqueous solution of sodium hydrogencarbonate (2.0 mL). The obtained mixture was filtered. The filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate (20 mL). To this solution was added petroleum ether (40 mL). The mixture was let stand for 2 h. The crystals were filtered and dried, giving 4.5 g of the title compound. The mother liquor was purified by chromatography (petroleum ether/ethyl acetate 2:1 to 0:1), giving further 1.2 g of the title compound and 0.6 g of unreacted ingenol. The total yield was 73 %, or 81 % based on recovered ingenol.

Example 3

[0147] Dry ingenol (15.00 g, 90 %, 38.75 mmol) was dissolved in acetone (630 mL) with stirring, and the solution was heated to 45 °C. A solution of methanesulfonic acid (0.745 g, 7.75 mmol) in acetone (10 mL) was added during 5 seconds. The solution was stirred at 45 °C for an additional 95 seconds, before a solution of triethylamine (1.35 mL, 0.98 g, 9.69 mmol) in acetone (10 mL) was added during 5 seconds. The mixture was cooled to 20 °C, and ethyl acetate (500 mL) was added. Most of the reaction solvent (650 mL) was distilled off under vacuum. Water (200 mL) was added to the remaining solution, and the mixture was agitated for 2 minutes. The water layer was removed, and the water wash was repeated once before the organic phase was concentrated under vacuum. The crude product contained 84 % of the title compound as determined by ¹H NMR spectroscopy. The residue was dissolved in toluene (75 mL) by heating to reflux temperature followed by slow cooling to 5 °C. After 4 hours

standing, the formed crystals were filtered off, rinsed with 5 °C toluene (2 x 5 mL) and dried under vacuum at 20 °C until constant weight. After 18 hours, ingenol-5,20-acetonide (8.97 g) was obtained.




Example 4

Preparation of [(Z)-2-methylbut-2-enoyl] 2,4,6-trichlorobenzoate

[0148] Angelic acid (601 mg, 6.0 mmol) was dissolved in dichloromethane (3.0 mL) under argon. Diisopropylethylamine (1.23 mL, 7.20 mmol) was added at 5-10 °C in a period of 1 min. To this solution was added 2,4,6-trichlorobenzoyl chloride (1.12 mL, 7.20 mmol) at 3-6 °C in a period of 4 min. After the reaction solution had been stirred at 2 °C for 45 min, petroleum ether (9.0 mL) was added. The obtained suspension was purified by flash chromatography (petroleum ether/dichloromethane 3:1), giving the title compound as a white solid (605 mg, 33 %).

¹H NMR (300 MHz, CDCl₃) δ 7.40 (s, 2H), 6.42 (qq, J = 7.4, 1.5 Hz, 1H), 2.09 (dq, J = 7.4, 1.5 Hz, 3H), 1.97 (p, J = 1.5 Hz, 3H) (¹H NMR data: see also Matthew, B et al.; Org Lett. 2007, 9, 663-666).




Example 5

Preparation of angelic anhydride

[0149] To a solution of angelic acid (5 g, 50 mmol) in dichloromethane (100 mL) was added *N,N'*-dicyclohexylcarbodiimide (8.6 mL, 60 % in xylene, 25 mmol) at room temperature. The reaction mixture was stirred at this temperature for 1 h. The precipitate was filtered off. The filtrate was concentrated in vacuo. The residue was purified by chromatography (petroleum ether/ethyl acetate 10:1), giving 4.3 g of the title compound as an oil (94 %).

¹H NMR (300 MHz, CDCl₃) δ 6.37 - 6.25 (m, 2H), 2.06 (dq, J = 7.4, 1.5 Hz, 6H), 1.97 - 1.93 (m, 6H).



Preparation of ingenol-5,20-acetonide-3-angelate (compound 2)

Example 6

[0150] A mixture of ingenol-5,20-acetonide (233 mg, 0.60 mmol), [(Z)-2-methylbut-2-enoyl] 2,4,6-trichlorobenzoate (231 mg, 0.75 mmol), and sodium hydrogencarbonate* (75.6 mg, 0.90 mmol) in toluene (2.5 mL) was stirred at 100 °C for 22 h. The mixture was then filtered and washed with toluene. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 19:1 → heptane/ethyl acetate 3:2), giving the title compound as a white solid (215 mg, 76 % yield).

* In the absence of sodium hydrogencarbonate, the product obtained contained 2-3 % of ingenol-5,20-acetonide-3-tiglate.

¹H NMR (300 MHz, CDCl₃) δ 6.13 - 6.03 (m, 2H), 5.81 - 5.75 (m, 1H), 5.66 (s, 1H), 4.27 - 4.08 (m, 3H), 4.02 (s, 1H), 3.19 (s, 1H), 2.68 - 2.53 (m, 1H), 2.27 (ddd, J = 15.8, 9.1, 3.0 Hz, 1H), 2.02 - 1.95 (m, 3H), 1.94 - 1.87 (m, 3H), 1.81 - 1.68 (m, 4H), 1.47 (s, 3H), 1.43 (s, 3H), 1.09 (s, 3H), 1.05 (s, 3H), 0.98 (d, J = 7.1 Hz, 3H), 0.90 (dd, J = 11.9, 8.4 Hz, 1H), 0.69 (td, J = 8.7, 6.4 Hz, 1H).


Example 7

[0151] A mixture of ingenol-5,20-acetonide (1.32 g, 3.40 mmol), angelic anhydride (0.72 g, 3.94 mmol), and cesium carbonate (1.66 g, 5.10 mmol) in acetonitrile (26 mL) was stirred at room temperature for 2 h. The mixture was taken up in dichloromethane (30 mL) and washed with water. The aqueous phase was extracted three times with dichloromethane (3 × 4 mL). The combined organic phases were dried over sodium sulfate and concentrated in vacuo. The residue was purified by chromatography (petroleum ether/ethyl acetate 8:1), giving 1.46 g of the title compound (91 %) as a white solid.

Example 8

[0152] Ingenol-5,20-acetonide (10.00 g, 25.74 mmol) was dissolved in tetrahydrofuran (100

mL) with stirring, and the solution was cooled to 10-15 °C. A solution of lithium hexamethyldisilazide in tetrahydrofuran (1.0 M, 29.6 mL, 29.6 mmol) was added over a period of 10 minutes. Then a solution of angelic anhydride (5.51 mL, 5.62 g, 30.8 mmol) in tetrahydrofuran (70 mL) was added during 15 minutes. Ethyl acetate (200 mL) was added, and most of the reaction solvent (200 mL) was distilled off under vacuum. Water (75 mL) was added to the remaining solution, and the mixture was agitated for 2 minutes. The water layer was removed, and the water wash was repeated once before the organic phase was concentrated under vacuum. The residue was dissolved in methanol (61 mL) by heating to reflux temperature followed by slow cooling to 5 °C. After 4 hours standing, the formed crystals were filtered off, rinsed with 5 °C methanol (2 x 5 mL) and dried under vacuum at 20 °C until constant weight. After 18 hours, ingenol-5,20-acetonide-3-angelate (8.78 g) was obtained.



Preparation of ingenol-3-angelate (compound 3)

Example 9

[0153] Ingenol-5,20-acetonide-3-angelate (7 mg, 0.015 mmol) in methanol, which contained 1 % of concentrated aqueous hydrochloric acid solution, was stirred at room temperature for 1 h. The solution was diluted with ethyl ether. Water was added. After phase separation, the aqueous phase was extracted with ethyl ether. The combined organic phases were dried and concentrated in vacuo. The residue was purified by chromatography (petroleum ether/ethyl acetate 1:1), furnishing the product (4 mg, 63 % yield).

^1H NMR (300 MHz, CDCl_3) δ 6.17 (qq, $J = 7.3, 1.4$ Hz, 1H), 6.08-6.02 (m, 2H), 5.54 (s, 1H), 4.29 (d, $J = 4.5$ Hz, 1H), 4.22 - 4.01 (m, 4H), 3.48 (s, 1H), 2.60 - 2.46 (m, 1H), 2.40 - 2.17 (m, 2H), 2.02 (dq, $J = 7.2, 1.4$ Hz, 3H), 1.95-1.91 (m, 3H), 1.83 - 1.68 (m, 4H), 1.09 (s, 3H), 1.05 (s, 3H), 1.01 - 0.82 (m, 4H), 0.77 - 0.61 (m, 1H).

Example 10

[0154] A solution of ingenol-5,20-acetonide-3-angelate (1.46 g, 3.10 mmol) in methanol (30 mL), which contained 0.5 % of concentrated aqueous hydrochloric acid solution, was stirred at room temperature for 1 h. The solution was then diluted with toluene and washed with water. The aqueous phase was extracted with ethyl ether. The combined organic phases were dried

and concentrated in vacuo. The residue was purified by chromatography (petroleum ether/ethyl acetate 1:1 to 0:1), giving the product (1.20 g, 90 %), which contained 2 % of ingenol-3-tiglate.

Separation of ingenol angelate and ingenol tiglate by Preparative HPLC/MS:

Preparative HPLC/MS was performed on a Dionex APS-system with two PP150 preparative pumps and a Thermo MSQ Plus mass spectrometer.

Column: XTerra C-18, 150 x 19 mm, 5 μ m;

Loading: 50 mg of ingenol angelate in 0.35 mL of acetonitrile;

Solvent system: eluent A: solution of 0.1 % HCOOH in H₂O, eluent B: solution of 0.1 % HCOOH in acetonitrile

Flow rate: 18 mL/min; Run: 40 % A/60 % B; isocratic for 20 min.

The fractions were collected based on ion traces of relevant ions (MS-detector: MSQ from Dionex) and PDA signal (240-400 nm; detector: UVD 340 U from Dionex)

Example 11

[0155] Ingenol-5,20-acetonide-3-angelate (47.1 mg, 0.10 mmol) was dissolved in tetrahydrofuran (0.47 mL) under argon. An aqueous solution of hydrochloric acid (4 M, 4.7 μ L) was added under ice-cooling. The solution was stirred at room temperature for 24 h. The solution was concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 5:1 $\rightarrow$ heptane/ethyl acetate 1:1), furnishing the title compound (30.8 mg, 72 % yield) besides starting material (6.1 mg, 13 %).

Example 12

[0156] Ingenol-5,20-acetonide-3-angelate (6.00 g, 12.75 mmol) was suspended in 2-propanol (152 mL) and stirred at 20 °C. A solution of phosphoric acid (15.00 g, 153 mmol) in water (8 mL) was added, and the suspension was heated to 30-35 °C. The resulting clear solution was stirred for 7 days. The reaction mixture was cooled to 20 °C and diluted with methyl *tert*-butyl ether (500 mL). Water (100 mL) was added, and the mixture was agitated for 2 minutes. The water layer was removed, and the water wash was repeated four times before the organic phase was concentrated under vacuum. Methyl *tert*-butyl ether (200 mL) was added followed by concentration. The crude product contained > 95 % ingenol-3-angelate. The residue was dissolved in acetonitrile (20 mL) by heating to reflux temperature. The solution was cooled to 5 °C. After 24 hours standing at 5 °C, the precipitated product was filtered off, rinsed with 5 °C acetonitrile (2 x 5 mL) and dried under vacuum at 20 °C until constant weight. After 18 hours, ingenol-3-angelate (3.91 g) was obtained.

Preparation of compounds of general formula (IV) from ingenol:

Example 13**Preparation of symmetrical ketals**

[0157] The procedure described in Example 1 for the synthesis of ingenol-5,20-acetonide was used for the preparation of symmetrical ketals, replacing acetone with 3-pentanone, 2,4-dimethyl-3-pentanone, 2,6-dimethyl-4-heptanone, cyclopentanone or cyclohexanone, on a scale of 25-50 mg ingenol.

[0158] Product distribution is shown in table 1A

Products are shown in table 1B

Table 1A

Synthesis of symmetrical ketals - acid catalyzed	
Reagent and solvent	Product distribution ^a
Propanone (acetone)	I-5,20-A (70-75 %)
	I-3,4-A (5-10 %)
	I-3,4:5,20-A (10-15 %)
	I (5-10 %)
3-Pentanone	I-5,20-X (70-75 %)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (10-15 %)
	I (5-10 %)
2,4-Dimethyl-3-pentanone	I-5,20-X (0-5 %)
	I-3,4-X (0-5 %)
	I-3,4:5,20-X (0-5 %)
	I (90-95 %)
2,6-Dimethyl-4-heptanone	I-5,20-X (15-20 %)
	I-3,4-X (15-20 %)
	I-3,4:5,20-X (0-5 %)
	I (60-65 %)
Cyclopentanone	I-5,20-X (70-75 %)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (10-15 %)
	I (5-10 %)
	I-5,20-X (70-75 %)

Synthesis of symmetrical ketals - acid catalyzed	
Reagent and solvent	Product distribution ^a
Cyclohexanone	I-3,4-X (5-10 %)
	I-3,4:5,20-X (10-15 %)
	I (5-10 %)
^a The product distributions were estimated from ¹ H NMR and/or TLC data.	

Table 1B

Ingenol-5,20-ketal	Ingenol-3,4-ketal	Ingenol-3,4:5,20-diketal
R ¹¹ = R ¹² = Methyl Ingenol-5,20-acetonide	R ¹³ = R ¹⁴ = Methyl Ingenol-3,4-acetonide	R ¹¹ = R ¹² = R ¹³ = R ¹⁴ = Methyl Ingenol-3,4:5,20-diacetonide
R ¹¹ = R ¹² = Ethyl Ingenol-5,20-(3-pentylidene)-ketal (Compound 4)	R ¹³ = R ¹⁴ = Ethyl Ingenol-3,4-(3-pentylidene)-ketal	R ¹¹ = R ¹² = R ¹³ = R ¹⁴ = Ethyl Ingenol-3,4:5,20-di[(3-pentylidene)-ketal]
R ¹¹ = R ¹² = Prop-2-yl Ingenol-5,20-(2,4-dimethyl-3-pentylidene)-ketal (Compound 5)	R ¹³ = R ¹⁴ = Prop-2-yl Ingenol-3,4-(2,4-dimethyl-3-pentylidene)-ketal	R ¹¹ = R ¹² = R ¹³ = R ¹⁴ = Prop-2-yl Ingenol-3,4:5,20-di[(2,4-dimethyl-3-pentylidene)-ketal]
R ¹¹ = R ¹² = 2-Methylprop-1-yl Ingenol-5,20-(2,6-dimethyl-4-heptylidene)-ketal (Compound 6)	R ¹³ = R ¹⁴ = 2-Methylprop-1-yl Ingenol-3,4-(2,6-dimethyl-4-heptylidene)-ketal	R ¹¹ = R ¹² = R ¹³ = R ¹⁴ = 2-Methylprop-1-yl Ingenol-3,4:5,20-di[(2,6-dimethyl-4-heptylidene)-ketal]
R ¹¹ R ¹² = CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-5,20-cyclopentylidene-ketal (Compound 7)	R ¹³ R ¹⁴ = CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-3,4-cyclopentylidene-ketal	R ¹¹ R ¹² = R ¹³ R ¹⁴ = CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-3,4:5,20-di(cyclopentylidene-ketal)
R ¹¹ R ¹² = CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-5,20-cyclohexylidene-ketal (Compound 8)	R ¹³ R ¹⁴ = CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-3,4-cyclohexylidene-ketal	R ¹¹ R ¹² = R ¹³ R ¹⁴ = CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ Ingenol-3,4:5,20-di(cyclohexylidene-ketal)

Example 14**Preparation of non- symmetrical ketals**

[0159] The general procedure described in Example 15 was used for the preparation of non-symmetrical ketals, replacing the acetal/aldehyde with 3,3-dimethyl-2-butanone, acetophenone or (1,1-dimethoxyethyl)benzene, on a scale of 25-50 mg ingenol.

Product distribution is shown in table 2A




Products are shown in table 2B

Table 2A

Synthesis of non-symmetrical ketals - acid catalyzed	
Reagent in THF	Product distribution ^a
3,3-Dimethyl-2-butanone	I-5,20-X (20-30 %)
	I-3,4-X (20-30 %)
	I-3,4:5,20-X (10-20 %)
	I (30-40 %)
	Several other products observed by TLC
Acetophenone	No conversion
(1,1-Dimethoxyethyl)benzene	I-5,20-X (10-20 %)
	I-3,4-X (30-40 %)
	I-3,4:5,20-X (10-20 %)
	I (30-40 %)
	Several other products observed by TLC

^a The product distributions were estimated from ¹H NMR and/or TLC data.

Table 2B

		
Ingenol-5,20-ketal	Ingenol-3,4-ketal	Ingenol-3,4:5,20-diketal
R ¹² = 1,1-Dimethylethyl Ingenol-5,20-(3,3-dimethyl-2-butylidene)-ketal (Compound	R ¹⁴ = 1,1-Dimethylethyl Ingenol-3,4-(3,3-dimethyl-2-butylidene)-	R ¹² = R ¹⁴ = 1,1-Dimethylethyl Ingenol-3,4:5,20-di[(3,3-dimethyl-2-

9)	ketal	butylidene)-ketal]
R ¹² = Phenyl Ingenol-5,20-(1-phenyl-1-ethylidene)-ketal (Compound 10)	R ¹⁴ = Phenyl Ingenol-3,4-(1-phenyl-1-ethylidene)-ketal	R ¹² = R ¹⁴ = Phenyl Ingenol-3,4:5,20-di[(1-phenyl-1-ethylidene)-ketal]

Example 15 (general procedure)**Preparation of acetals**

[0160] Ingenol (25 mg, 72 μ mol) was dissolved in tetrahydrofuran (622 μ L) at 20 °C. A solution of p-toluenesulfonic acid monohydrate in tetrahydrofuran (50 mg/mL, 0.26 M, 96 μ L, 25 μ mol) was added with stirring. The aldehyde/acetal (86 μ mol) was added, and the progress of the reaction was monitored by TLC. The data provided were obtained after 21 hours of reaction time.

Product distribution is shown in table 3A




Products are shown in table 3B

Table 3A

Synthesis of Acetals - acid catalyzed	
Reagent in THF	Product distribution ^a
Benzaldehyde	I-5,20-X (65-70 %) (One epimer)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (10-15 %)
	I (10-15 %)
	No epimers observed by TLC and ¹ H NMR
Benzaldehyde dimethylacetal	I-5,20-X (45-50 %) (One epimer)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (10-15 %)
	I (30-35 %)
	No epimers observed by TLC
4-Methoxybenzaldehyde	Several other products observed by TLC
	I-5,20-X (10-20 %)
	I-3,4-X (10-15 %)
	I-3,4:5,20-X (5-10 %)
	I (60-70 %)
	No epimers observed by TLC

Synthesis of Acetals - acid catalyzed	
Reagent in THF	Product distribution ^a
2,4-Dimethoxybenzaldehyde	I-5,20-X (10-15 %)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (5-10 %)
	I (70-75 %)
	One other product observed by TLC
4-Nitrobenzaldehyde	I-5,20-X (15-20 %)
	I-3,4-X (5-10 %)
	I-3,4:5,20-X (5-10 %)
	I (65-70 %)
	No epimers observed by TLC
2,4,6-Trimethylbenzaldehyde	I-5,20-X (15-20 %)
	I-3,4-X (0-5 %)
	I-3,4:5,20-X (10-15 %)
	I (65-70 %)
	No epimers observed by TLC
Trimethylacetaldehyde	I-5,20-X (45-50 %)
	I-3,4-X (10-15 %)
	I-3,4:5,20-X (10-15 %)
	I (25-30 %)
	No epimers observed by TLC
^a The product distributions were estimated from ¹ H NMR and/or TLC data.	

Table 3B

 <p>Ingenol-5,20-acetal</p>	 <p>Ingenol-3,4-acetal</p>	 <p>Ingenol-3,4:5,20-diacetal</p>
R ¹² = Phenyl Ingenol-5,20-benzylidene-acetal (Compound 11)	R ¹⁴ = Phenyl Ingenol-3,4-benzylidene-acetal	R ¹² = R ¹⁴ = Phenyl Ingenol-3,4:5,20-di(benzylidene-acetal)

R ¹² = 4-Methoxyphenyl Ingenol-5,20-(4-methoxybenzylidene)-acetal (Compound 12)	R ¹⁴ = 4-Methoxyphenyl Ingenol-3,4-(4-methoxybenzylidene)-acetal	R ¹² = R ¹⁴ = 4-Methoxyphenyl Ingenol-3,4:5,20-di[(4-methoxybenzylidene)-acetal]
R ¹² = 2,4-Dimethoxyphenyl Ingenol-5,20-(2,4-dimethoxybenzylidene)-acetal (Compound 13)	R ¹⁴ = 2,4-Dimethoxyphenyl Ingenol-3,4-(2,4-dimethoxybenzylidene)-acetal	R ¹² = R ¹⁴ = 2,4-Dimethoxyphenyl Ingenol-3,4:5,20-di[(2,4-dimethoxybenzylidene)-acetal]
R ¹² = 4-Nitrophenyl Ingenol-5,20-(4-nitrobenzylidene)-acetal (Compound 14)	R ¹⁴ = 4-Nitrophenyl Ingenol-3,4-(4-nitrobenzylidene)-acetal	R ¹² = R ¹⁴ = 4-Nitrophenyl Ingenol-3,4:5,20-di[(4-nitrobenzylidene)-acetal]
R ¹² = 2,4,6-Trimethylphenyl Ingenol-5,20-(2,4,6-trimethylbenzylidene)-acetal (Compound 15)	R ¹⁴ = 2,4,6-Trimethylphenyl Ingenol-3,4-(2,4,6-trimethylbenzylidene)-acetal	R ¹² = R ¹⁴ = 2,4,6-Trimethylphenyl Ingenol-3,4:5,20-di[(2,4,6-trimethylbenzylidene)-acetal]
R ¹² = 1,1-Dimethylethyl Ingenol-5,20-(2,2-dimethyl-1-propylidene)-acetal (Compound 16)	R ¹⁴ = 1,1-Dimethylethyl Ingenol-3,4-(2,2-dimethyl-1-propylidene)-acetal	R ¹² = R ¹⁴ = 1,1-Dimethylethyl Ingenol-3,4:5,20-di[(2,2-dimethyl-1-propylidene)-acetal]

Example 16 (general procedure)**Synthesis of benzylidene acetal**

[0161] Ingenol (25 mg, 72 μ mol) was dissolved in the solvent (622 μ L) at 20 °C with stirring. For reactions conducted in pyridine, no further base was added. For reactions conducted in acetone or *N,N*-dimethylformamide, potassium carbonate (158 μ mol) was added. For reactions conducted in tetrahydrofuran or 2-methyltetrahydrofuran, lithium hexamethyldisilazide (158 μ mol) was added as a solution in tetrahydrofuran (1.0 M). A solution/suspension of the reagent (79 μ mol) in the solvent (96 μ L) was added dropwise. The progress of the reaction was monitored by TLC. For slow reactions, the temperature was increased from 20 °C to 50 °C and eventually to the boiling point of the solvent. The reaction of ingenol with α,α -dibromotoluene in pyridine was conducted at 100 °C for 3 hours. The reaction of ingenol with α,α -bis(pyridinium)toluene dibromide in tetrahydrofuran was conducted at 50 °C for 1 hour.

Product distribution is shown in table 4A

Products are shown in table 4B

Table 4A

Synthesis of benzylidene acetal - base promoted			
Reagent	Solvent	Base	Product distribution ^a
α,α -Dichlorotoluene	Pyridine or acetone or DMF or MeTHF	K ₂ CO ₃ (in acetone and DMF) or LiHMDS (in MeTHF)	No conversion
α,α -Dibromotoluene	Pyridine	Pyridine	I-5,20-X (85-90 %) (One epimer)
			I-3,4-X (0-10 %)
			I-3,4:5,20-X (0-10 %)
			I (0-5 %)
α,α -Bis(pyridinium)toluene dibromide ^b	THF	LiHMDS	I-5,20-X (20-30 %)
			I-3,4-X (20-30 %)
			I-3,4:5,20-X (20-30 %)
			I (20-30 %)
			Several other products observed by TLC
α,α -Bis(4-(dimethyl-amino)pyridinium)toluene dibromide ^c	Pyridine or DMF or THF	K ₂ CO ₃ (in DMF) or LiHMDS (in THF)	No conversion
^a The product distributions were estimated from ¹ H NMR and/or TLC data. ^b Preparation: cf. Acta Chem. Scand. 1972, 26, 3895-3901 and J. Org. Chem. 2007, 72, 9854-9856 (compound 1 in Scheme 2). ^c Prepared by treatment of α,α -dibromotoluene (10 g, 0.04 mmol) with 4-(dimethylamino)pyridine (10.78 g, 0.088 mmol) in acetone (20 mL) at reflux for 1 hour.			

Example 17**Synthesis of orthoformates**

[0162] The general procedure described in Example 15 was for the preparation of orthoformates, replacing the aldehyde/acetal with trimethyl orthoformate, triethyl orthoformate

or tri(prop-2-yl) orthoformate, on a scale of 25-100 mg ingenol.

Product distribution is shown in table 5A




Products are shown in table 5B

Table 5A

Synthesis of orthoformates - acid catalyzed	
Reagent in THF	Product distribution ^a
Trimethyl orthoformate	I-5,20-X (75-80 %, 60:40 mixture of epimers)
	I-3,4-X (0-10 %)
	I-3,4:5,20-X (0-10 %)
	I (10-15 %)
Triethyl orthoformate	I-5,20-X (75-80 %, 60:40 mixture of epimers)
	I-3,4-X (0-10 %)
	I-3,4:5,20-X (0-10 %)
	I (10-15 %)
Tri(prop-2-yl) orthoformate	I-5,20-X (75-80 %, 60:40 mixture of epimers)
	I-3,4-X (0-10 %)
	I-3,4:5,20-X (0-10 %)
	I (10-15 %)

^a The product distributions were estimated from ¹H NMR and TLC data.

Table 5B

 <p>Ingenol-5,20-orthoformate</p>	 <p>Ingenol-3,4-orthoformate</p>	 <p>Ingenol-3,4:5,20-diorthoformate</p>
R ²² = Methyl Ingenol-5,20-methyl-orthoformate (Compound 17)	R ²⁴ = Methyl Ingenol-3,4-methyl-orthoformate	R ²² = R ²⁴ = Methyl Ingenol-3,4:5,20-di(methyl-orthoformate)
R ²² = Ethyl Ingenol-5,20-ethyl-orthoformate (Compound 18)	R ²⁴ = Ethyl Ingenol-3,4-ethyl-orthoformate	R ²² = R ²⁴ = Ethyl Ingenol-3,4:5,20-di(ethyl-orthoformate)

R ²² = Prop-2-yl Ingenol-5,20-(prop-2-yl)-orthoformate (Compound 19)	R ²⁴ = Prop-2-yl Ingenol-3,4-(prop-2-yl)-orthoformate	R ²² = R ²⁴ = Prop-2-yl Ingenol-3,4:5,20-di[(prop-2-yl)-orthoformate]
---	--	---

Example 18**Synthesis of Methyl orthoformate (methoxymethylene acetal)**

[0163] The procedure described in Example 16 was employed using dichloromethyl methyl ether as the reagent, and using lithium hexamethyldisilazide in tetrahydrofuran. The reaction was conducted in tetrahydrofuran at 20 °C for 30 minutes.

Table 6A

Methyl orthoformate (methoxymethylene acetal) - base promoted			
Reagent	Solvent	Base	Product distribution ^a
Dichloromethyl methyl ether	THF	LiHMDS	I-5,20-X (10-15 %)
			I-3,4-X (10-15 %)
			I (50-60 %)
			Several other products observed by TLC
^a The product distribution was estimated from TLC data.			

Synthesis of compounds of general formula (VI')**Reference example: Synthesis of ingenol-5,20-acetonide-3-angelate using Angelic acid (AngOH)****Reference Example 19A (general procedure)**

[0164] Ingenol-5,20-acetonide (10.0 mg, 26 µmol) and angelic acid (2.6 mg, 26 µmol) were dissolved in the solvent (175 µL) at 20 °C with stirring. For reactions conducted in the presence of base, either 4-(dimethylamino)pyridine (6.3 mg, 52 µmol) or *N,N*-diisopropylethylamine (9 µL, 6.7 mg, 52 µmol) was added before the dropwise addition of a solution/suspension of the

coupling reagent (26-52 μmol) in the solvent (75 μL). The progress of the reaction was monitored by TLC and ^1H NMR spectroscopy.

Reference Example 19B

[0165] Ingenol-5,20-acetonide (25.0 mg, 64 μmol), angelic acid (6.4 mg, 64 μmol) and 2-chloro-1-methyl-pyridinium iodide (19.7 mg, 77 μmol) (Mukaiyama's reagent) were suspended in toluene (108 μL). Tributylamine (37 μL , 29 mg, 155 μmol) was added, and the mixture was stirred at 60 °C for 18 hours. The progress of the reaction was monitored by TLC and ^1H NMR spectroscopy.

[0166] Product distribution and reaction conditions for examples 19A and 19B are shown in table 7A

Products are shown in table 7B


The (E)/(Z) ratio is the Tiglate/Angelate ratio.


Table 7A

Synthesis of ingenol-5,20-acetonide-3-angelate using Angelic acid (AngOH)			
Reagent	Solvent	Products formed (crude yield) ^a	(E)/(Z) ^b
EDCI	CDCl_3	Ang ₂ O	N/A
EDCI/DMAP	DCM	I-5,20-A-3-Tig (50-60 %) and Ang ₂ O, AngOTig and Tig ₂ O	96:4
DCC	CDCl_3	I-5,20-A-3-Ang (2 %) and Ang ₂ O	1:99
DCC	PhMe	No conversion	N/A
DCC/DIPEA	PhMe	No conversion	N/A
DCC/DMAP	CDCl_3	I-5,20-A-3-Tig (75 %)	85:15
HATU/DIPEA	DMF	Initial formation of AngOAt (100 %) Subsequent formal hydrolysis to AngOH and HOAt	N/A
2-Chloro-1-methyl-pyridinium iodide / Bu ₃ N	PhMe	I-5,20-A-3-Tig (30-40 %) and Ang ₂ O, AngOTig and Tig ₂ O	90:10
^{a,b} The yields and (E)/(Z) ratios of were estimated from ^1H NMR and TLC data.			
^b (E)/(Z) $\geq$ 1:99 due to a content of 0.5-1 % TigOH in AngOH.			

[0167] The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang ratio

Table 7B





Synthesis of ingenol-5,20-acetonide-3-angelate using Angelic anhydride

Example 20A

[0168] The procedure for the synthesis of ingenol-5,20-acetonide-3-angelate described in Example 8 was used for lithium hexamethyldisilazide in methyl *tert*-butyl ether, lithium hexamethyldisilazide in tetrahydrofuran, sodium hexamethyldisilazide in tetrahydrofuran and potassium hexamethyldisilazide in tetrahydrofuran on a scale of 25 mg - 10 g ingenol-5,20-acetonide.

Example 20B

[0169] The experimental procedure for the synthesis of ingenol-5,20-acetonide-3-angelate using cesium carbonate is described in Example 7.

Example 20C (general procedure)

[0170] Ingenol-5,20-acetonide (15.0 mg, 39 μ mol) was dissolved in pyridine (386 μ L) or tetrahydrofuran (386 μ L) at 20 °C with stirring. For the reaction conducted in pyridine, angelic anhydride (10.6 mg, 58 μ mol) was added. For the reaction conducted in tetrahydrofuran, 4-(dimethylamino)pyridine (7.1 mg, 58 μ mol) was added before the addition of angelic anhydride (10.6 mg, 58 μ mol). The progress of the reaction was monitored by TLC and ^1H NMR spectroscopy.

[0171] Product distribution and reaction conditions for examples 20A, 20B and 20C are shown in table 8A

Products are shown in table 7B

The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang -ratio.

Table 8

Synthesis of ingenol-5,20-acetonide-3-angelate using_Angelic anhydride (Ang ₂ O)			
Reagent	Solvent	Products formed (crude yield) ^a	(E)/(Z) ^b
LiHMDS	MTBE	I-5,20-A-3-Ang (> 95 %)	2:98
		Slower conversion in MTBE than in THF due to low solubility	
LiHMDS	THF	Rapid and clean conversion into I-5,20-A-3-Ang (> 95 %)	2:98
NaHMDS	THF	I-5,20-A-3-Ang (> 95 %)	2:98
		Slower conversion than with LiHMDS requiring larger excess of reagents	
KHMDS	THF	I-5,20-A-3-Ang (> 90 %)	2:98
		Slower and less clean conversion than with LiHMDS and NaHMDS	
Cs ₂ CO ₃	MeCN	I-5,20-A-3-Ang (> 95 %)	2:98
Pyridine	Pyridine	I-5,20-A-3-Tig (55 %)	96:4
DMAP	THF	I-5,20-A-3-Tig (55 %)	96:4
^{a,b} The yields and (E)/(Z) ratios were estimated from ¹ H NMR and TLC data. ^b (E)/(Z) ≥ 2:98 due to a content of 1.5-2 % AngOTig in Ang ₂ O. The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang ratio			

Synthesis of ingenol-5,20-acetonide-3-angelate using Angeloyl chloride

Example 21A

[0172] The procedure described in Example 8 for angelic anhydride was employed for the reaction between angeloyl chloride and ingenol-5,20-acetonide using lithium hexamethyldisilazide in tetrahydrofuran. The experiment was conducted on a scale of 25 mg ingenol-5,20-acetonide.

Example 21B

[0173] The procedure described in Example 20C for angelic anhydride was employed, replacing angelic anhydride with angeloyl chloride, for the reaction between angeloyl chloride and ingenol-5,20-acetonide in ethyl ether without base (for reference), in tetrahydrofuran without base (for reference), in pyridine and in tetrahydrofuran with 4-(dimethylamino)pyridine (1.5 equiv.) added. The experiments were conducted on a scale of 15-50 mg ingenol-5,20-

acetonide.

[0174] Product distribution and reaction conditions for examples 21A and 21B are shown in table 9

Products are shown in table 7B

The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang ratio.

Table 9

Synthesis of ingenol-5,20-acetonide-3-angelate using Angeloyl chloride (AngCl) ^c			
Reagent	Solvent	Products formed (crude yield) ^a	(E)/(Z) ^b
LiHMDS	THF	I-5,20-A-3-Ang (60 %) and I-5,20-A (30 %) and other impurities (10 %)	3:97
None (reference example)	Ethyl ether	No conversion, low solubility	N/A
None (reference example)	THF	No reaction	N/A
Pyridine	Pyridine	I-5,20-A-3-Tig (60-70 %) and impurities (30 %)	96:4
DMAP	THF	I-5,20-A-3-Tig (50-60 %)	96:4
^{a,b} The yields and (E)/(Z) ratios were estimated from ¹ H NMR and TLC data. ^b (E)/(Z) ≥ 3:97 due to isomerization of AngCl to TigCl during storage. The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang ratio ^c Preparation: cf. Tetrahedron Letters 1977, 38, 3379-3382 (compound 2).			

Synthesis of ingenol-5,20-acetonide-3-angelate using Methyl angelate

Example 22

[0175] The procedure described in Example 8 for angelic anhydride was employed for the reaction between methyl angelate and ingenol-5,20-acetonide using lithium hexamethyldisilazide in tetrahydrofuran. The experiment was conducted on a scale of 25 mg ingenol-5,20-acetonide.

Table 10

Synthesis of ingenol-5,20-acetonide-3-angelate using Methyl angelate (AngOMe) ^c			
Reagent	Solvent	Product formed (crude yield) ^a	(E)/(Z) ^b
LiHMDS	THF	I-5,20-A-3-Ang (7 %)	1:99
^{a,b} The yield and (E)/(Z) ratio were estimated from ¹ H NMR and TLC data.			

^b (E)/(Z) = 1:99 due to a content of 0.5-1 % TigOMe in AngOMe.

The (E)/(Z) ratio is the I-5,20-A-3-Tig/I-5,20-A-3-Ang ratio

^c Prepared by dropwise addition of a solution of (trimethylsilyl)diazomethane in ethyl ether (2.0 M, 18.8 mL, 38 mmol) over a period of 175 minutes at 20 °C to a stirred solution of angelic acid (3.0 g, 30.0 mmol) in dichloromethane/methanol = 3:2 (30 mL). The reaction mixture was concentrated, and methyl angelate was purified by vacuum distillation. Also see J. Org. Chem. 1950, 15, 680-684.

¹H NMR (300 MHz, CDCl₃) δ 6.06 (qq, 1H), 3.74 (s, 3H), 1.98 (dq, 3H), 1.89 (quintet, 3H).

Example 23 (general procedure)

Preparation of ingenol-3-angelate from ingenol-5,20-acetonide-3-angelate

[0176] Ingenol-5,20-acetonide-3-angelate (15 mg, 35 μmol) was dissolved/suspended in the organic solvent (331 μL) at 20 °C. A solution of the catalyst in water (17 μL) was added with stirring resulting in a concentration of 0.1 M with respect to ingenol-5,20-acetonide-3-angelate. For formic acid/water (95:5), acetic acid/water (95:5) and trifluoroacetic acid/water (95:5), ingenol-5,20-acetonide-3-angelate was dissolved in the solvent mixture. The progress of the reaction was monitored by TLC and ¹H NMR spectroscopy.

Product distribution and reaction conditions for examples 23 is shown in table 11A

Products are shown in table 11B

Table 11A

Catalyst	pK _a	Mol ratio ^b	Solvent	Temp °C	(E)/(Z) ^a at complete conversion (days)	(E)/(Z) ^a after n days (days)	Comment
HCl	-8.0	1	THF/H ₂ O 95:5	20	5:95 (4)	19:81 (11)	Clean
HCl	-8.0	1	MeOH/H ₂ O 95:5	20	3:97 (< 1)	6:94 (2)	Clean
HCl	-8.0	1	IPA/H ₂ O 95:5	20	3:97 (3)	14:86 (11)	Clean
MSA	-2.6	2	THF/H ₂ O 95:5	20	2:98 (3)	2:98 (4)	Clean
MSA	-2.6	2	IPA/H ₂ O 95:5	20	2:98 (2)	3:97 (10)	Clean
AG							

Catalyst	pK _a	Mol ratio ^b	Solvent	Temp °C	(E)/(Z) ^a at complete conversion (days)	(E)/(Z) ^a after n days (days)	Comment
50WX2 cation exch. resin	-2.6	2	IPA/H ₂ O 95:5	20	2:98 (2)	3:97 (13)	Clean
TFA	-0.25	6.5	IPA/H ₂ O 95:5	20	3:97 (> 4)	3:97 (4)	Esterification ^c
TFA	-0.25	124	TFA/H ₂ O 95:5	20	N/A	N/A	Dec. ^d
H ₃ PO ₄	2.12	12	IPA/H ₂ O 95:5	30	2:98 (7)	2:98 (10)	Clean
HCOOH	3.77	252	HCOOH/H ₂ O 95:5	20	N/A	N/A	Dec. ^d
AcOH	4.76	166	AcOH/H ₂ O 95:5	20	2:98 (> 4)	2:98 (4)	Esterification ^c

^a The (E)/(Z) ratios were estimated by ¹H NMR spectroscopy.



^a (E)/(Z) ≥ 2:98 due to a content of 1-2 % I-5,20-A-3-Tig in I-5,20-A-3-Ang. ^b Number of moles catalyst relative to I-5,20-A-3-Ang.

^c Ester formation between catalyst and the ingenol 20-position.

^d Decomposition.

The (E)/(Z) ratio is the I-3-Tig/I-3-Ang ratio



Table 11B



Example 24**Ingenol-5,20-(di(*tert*-butyl)silylene)-ether (Compound 20)**

[0177] To a solution of ingenol (50.4 mg, 0.145 mmol) and 2,6-lutidine (46.7 mg, 0.436 mmol) in *N,N*-dimethylformamide (0.25 mL) was added di(*tert*-butyl)silyl bis(trifluoromethanesulfonate) (76.6 mg, 0.174 mmol) at 0 °C. The obtained solution was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous solution of sodium hydrogencarbonate. The mixture was then extracted twice with ethyl acetate. The combined organic phases were washed with saturated aqueous solution of sodium chloride, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 1:0→1:1), giving the title compound (35.7 mg, 50%) as a white foam.



¹H NMR (300 MHz, CDCl₃) δ 6.02 (d, *J* = 5.1 Hz, 1H), 5.96 (q, *J* = 1.5 Hz, 1H), 4.47 (d, *J* = 12.5 Hz, 1H), 4.33 - 4.18 (m, 4H), 3.89 (s, 1H), 2.57 - 2.30 (m, 2H), 1.87 (d, *J* = 1.5 Hz, 3H), 1.76 (ddd, *J* = 15.8, 6.3, 3.9 Hz, 1H), 1.11 (s, 3H), 1.05 (s, 3H), 1.02-0.95 (m, 22H), 0.90 (dd, *J* = 11.8, 8.4 Hz, 1H), 0.75 - 0.61 (m, 1H).

**Example 25****Ingenol-5,20-(di(*tert*-butyl)silylene)-ether-3-angelate (Compound 21)**

[0178] A mixture of ingenol-5,20-(di(*tert*-butyl)silylene)-ether (35.5 mg, 0.073 mmol), [(*Z*)-2-

methylbut-2-enyl] 2,4,6-trichlorobenzoate (29.7 mg, 0.097 mmol), and sodium hydrogencarbonate (10.2 mg, 0.12 mg) in toluene (0.3 mL) was stirred under argon atmosphere at 100 °C for 20 h. After being cooled to room temperature, the reaction mixture was filtered and washed with toluene. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 1:0→4:1), giving the title compound as a white foam (23.4 mg, 56%).


^1H NMR (300 MHz, CDCl_3) δ 6.10 - 5.96 (m, 3H), 5.67 (s, 1H), 4.49 (d, J = 12.5 Hz, 1H), 4.35 - 4.21 (m, 3H), 3.64 (s, 1H), 2.64-2.52 (m, 1H), 2.46 - 2.27 (m, 1H), 2.01 - 1.93 (m, 3H), 1.91 (dq, J = 3.0, 1.5 Hz, 3H), 1.82 - 1.65 (m, 4H), 1.10-1.04 (m, 15H), 1.03 - 0.95 (m, 12H), 0.94 - 0.84 (m, 1H), 0.67 (ddd, J = 10.1, 8.4, 6.4 Hz, 1H).



Example 26

Ingenol-3-angelate

[0179] To a solution of ingenol-5,20-(di(*tert*-butyl)silylene)-ether-3-angelate (10.3 mg, 0.018 mmol) in tetrahydrofuran (0.1 mL) was added tetrabutylammonium fluoride (1 M in tetrahydrofuran, 0.054 mmol) under argon atmosphere at -20 °C. The solution was stirred at the same temperature for 15 min. The reaction was quenched with saturated aqueous solution of ammonium chloride. The mixture was extracted three times with ethyl acetate. The combined organic phases were dried over magnesium sulfate and concentrated. The residue was purified by chromatography (heptane/ethyl acetate 4:1→>1:1), giving the title compound (2.2 mg, 29%).





Example 27**Ingenol-20-(*tert*-butyldimethylsilyl)-ether (Compound 22)**

[0180] To a solution of ingenol (66.2 mg, 0.15 mmol) and 2,6-lutidine (48.2 mg, 0.45 mmol) in *N,N*-dimethylformamide (0.25 mL) was added *tert*-butyldimethylsilyl chloride (27.1 mg, 0.18 mmol). The solution was stirred at the same temperature for 30 min. The reaction was not complete. 2,6-Lutidine (16.1 mg, 0.15 mmol) and *tert*-butyldimethylsilyl chloride (18.1 mg, 0.12 mmol) were added. The mixture was stirred at room temperature for 1 h, taken up in aqueous solution of sodium hydrogencarbonate, and extracted three times with ethyl acetate. The combined organic phases were dried over magnesium sulfate and concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 3:1), providing an impure product. This impure product was subjected to a further chromatographic purification (dichloromethane/ethyl acetate 19:1→10:1), giving the title compound as a white foam (65.8 mg, 95%).



[0181] Also see: Opferkuch, H. J. et al., Z. Naturforsch. 1981, 36b, 878-887 (compound **10**)

¹H NMR (300 MHz, CDCl₃) δ 6.11 - 5.94 (m, 1H), 5.96 - 5.84 (m, 1H), 4.44 (broad s, 1H), 4.32 (s, 1H), 4.29 - 4.07 (m, 3H), 4.01 (s, 1H), 3.86 (s, 1H), 2.57 - 2.39 (m, 1H), 2.32 (ddd, J = 15.6, 9.1, 3.0 Hz, 1H), 1.85 (d, J = 1.4 Hz, 3H), 1.75 (ddd, J = 15.7, 6.2, 4.8 Hz, 1H), 1.11 (d, J = 7.1 Hz, 3H), 1.06 (s, 3H), 0.96 (dd, J = 7.6, 5.3 Hz, 3H), 0.89 (s, 9H), 0.88 - 0.80 (m, 1H), 0.78 - 0.60 (m, 1H), 0.08 (d, J = 1.3 Hz, 6H).

**Example 28****Ingenol-20-(*tert*-butyldimethylsilyl)-ether-3-angelate (Compound 23)**

[0182] A mixture of ingenol-20-(*tert*-butyldimethylsilyl)-ether (61.6 mg, 0.133 mmol), [(*Z*)-2-methylbut-2-enoyl] 2,4,6-trichlorobenzoate (54.4 mg, 0.177 mmol), and sodium hydrogencarbonate (16.8 mg, 0.20 mmol) in toluene (0.55 mL) was stirred under argon atmosphere at 100 °C for 17 h. After being cooled to room temperature, the reaction mixture was filtered and washed with toluene. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography (heptane/ethyl acetate 89:11→78:22), giving the title compound as a white foam (14.4 mg, 23%).

¹H NMR (300 MHz, CDCl₃) δ 6.08 (qd, *J* = 7.2, 1.4 Hz, 1H), 6.03 (q, *J* = 1.5 Hz, 1H), 5.96 (d, *J* = 4.6 Hz, 1H), 5.69 (s, 1H), 4.76 (s, 1H), 4.29 - 4.07 (m, 3H), 4.01 (s, 1H), 3.65 (s, 1H), 2.69 - 2.51 (m, 1H), 2.33 (ddd, *J* = 15.6, 9.6, 3.0 Hz, 1H), 2.03 - 1.95 (m, 3H), 1.97 - 1.85 (m, 3H), 1.82 - 1.65 (m, 4H), 1.07 (s, 3H), 1.03 (s, 3H), 0.96 (d, *J* = 7.2 Hz, 3H), 0.93 - 0.80 (m, 10H), 0.67 (td, *J* = 9.4, 6.4 Hz, 1H), 0.07 (s, 6H).



Example 29

Ingenol-3-angelate

[0183] Ingenol-20-(*tert*-butyldimethylsilyl)-ether-3-angelate (14.4 mg, 0.026 mmol) was dissolved in tetrahydrofuran (0.07 mL). To this solution was added hydrochloric acid in methanol (12.5 mM, 0.07 mL) at 0 °C. The solution was stirred at room temperature for 6.5 h and then subjected to flash chromatography (heptane/ethyl acetate 2:1→1:1), giving the title compound (4.6 mg, 40%) and the starting material (4.4 mg).

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in

compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US7449492B](#) [0003]
- [JP2008127287B](#) [0118]


Non-patent literature cited in the description

- **OGBOURNE, S. M.** Anti-cancer Drugs, 2007, vol. 18, 357-62 [0002]
- **SAYED, M.D.** Experienta, 1980, vol. 36, 1206-1207 [0003]
- **HOHMANN, J.** Planta Med., 2000, vol. 66, 291-294 [0003]
- **APPENDINO, G.J.** Nat. Prod., 1999, vol. 62, 76-79 [0003] [0003]
- **GIRIN, M.A.J.** Chromatogr., 1993, vol. 637, 206-208 [0003]
- **SORG, B.Z.** Naturforsch., 1982, vol. 37B, 748-756 [0004] [0004] [0004]
- **APPENDINO** Eur. J. Org. Chem., 1999, 3413- [0004] [0004]
- **OPFERKUCHZ.** Naturforschung, 1981, vol. 36B, 878- [0004] [0099]
- **BEEBY, P.** Tetrahedron Lett., 1977, vol. 38, 3379-3382 [0004]
- **HOSKINS, W.M.J.** Chem. Soc. Perkin Trans. 1, 1977, 538-544 [0004]
- **BOHLMANN, F.** Chem. Ber., 1970, vol. 103, 561-563 [0004]
- **P.G.M. WUTST.W. GREENE** Protective Groups in Organic Synthesis John Wiley 2007 000016-366 [0033]
- **P.J. KOCIENSKI G. THIEME** Protecting Groups 2003 0000 [0033] [0098] [0124]
- **P.G.M. WUTST.W. GREENE** Protective Groups in Organic Synthesis John Wiley 2007 0000 [0098] [0124]
- **J. OTERA** Esterification Wiley-VCH 2003 0000 [0116] [0120]
- **BEEBY, P.J.** Tetrahedron Lett., 1977, vol. 38, 3379-3382 [0117]
- **HARTMANN, B.** Tetrahedron Lett., 1991, vol. 32, 5077-5080 [0118] [0119]
- **BALL, B.** Org. Lett., 2007, vol. 9, 663-666 [0119]
- **HOSKINS, W.M.J.** Chem. Soc. Perkin Trans., 1977, vol. 1, 538-544 [0120]
- **NAM, N.-H.** Journal of Combinatorial Chemistry, vol. 203, 5479-545 [0120]
- **TENG, R.W.** Fitoterapia, 2009, vol. 80, 233-236 [0121]
- **OPFERKUCH, H. J. et al.** Z. Naturforsch., 1981, vol. 36b, 878-887 [0145] [0181]
- **MATTHEW, B et al.** Org Lett., 2007, vol. 9, 663-666 [0148]
- Acta Chem. Scand., 1972, vol. 26, 3895-3901 [0161]
- J. Org. Chem., 2007, vol. 72, 9854-9856 [0161]
- Tetrahedron Letters, 1977, vol. 38, 3379-3382 [0174]

- J. Org. Chem., 1950, vol. 15, 680-684 [\[Q175\]](#)


Patentkrav

- 1.** Fremgangsmåde til fremstilling af ingenol-3-angelat (2-methyl-2(Z)-butenonsyre (1*aR*,2*S*,5*R*,5*aS*,6*S*,8*aS*,9*R*,10*aR*)-5,5*a*-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1*a*,2,5,5*a*,6,9,10,10*a*-octahydro-1*H*-2,8*a*-methanocyclopenta[*a*]cyclopropa[*e*]cyclodecen-6-yl ester) (I) fra ingenol (II)




omfattende trinnene at:

- (a) omsætte én eller begge hydroxylgrupperne i positionerne 5 og 20 af ingenol med egnede hydroxylbeskyttelsesmidler, samme eller forskellig, for at opnå en forbindelse med den almene formel (III) eller (IV)



- hvor R_1 betegner hydrogen eller en hydroxylbeskyttelsesgruppe og R_2 betegner hydrogen eller en hydroxylbeskyttelsesgruppe, med det forbehold at ikke begge R_1 og R_2 betegner hydrogen, eller hvor D betegner en dihydroxylbeskyttelsesgruppe
- (b) esterificere hydroxylgruppen ved 3-positionen af forbindelserne (III) eller (IV) for at opnå forbindelser med den almene formel (V) eller (VI)




hvor R_1 , R_2 og D er som beskrevet ovenfor, og hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med:

- (i) methylangelat,
- 5 (ii) angeloylchlorid i tilstedeværelse af en base, i et egnet opløsningsmiddel,
- (iii) angelinsyreanhydrid, eller
- (iv) et blandet angelinsyreanhydrid;

og

- 10 (c) fjerne hydroxylbeskyttelsesgrupperne R_1 eller R_2 , eller R_1 og R_2 , eller D fra forbindelserne (V) eller (VI) for at opnå ingenol-3-angelat (I).



2. Fremgangsmåde ifølge krav 1 hvor R_1 betegner hydrogen eller en ether, acetal, ketal, silylether, ester, carbonat, eller en sulfenat afledt hydroxylbeskyttelses-
- 15 gruppe, og R_2 betegner hydrogen eller en ether, acetal, ketal, silylether, ester, carbonat, eller en sulfenat afledt hydroxylbeskyttelsesgruppe.

3. Fremgangsmåde ifølge krav 1, hvor D betegner en acetal, ketal, diacetal, diketal, orthoester, silyl, boronat eller en carbonat afledt dihydroxylbeskyttelses-
- 20 gruppe.

4. Fremgangsmåde ifølge krav 1 eller 2 hvor R_1 er valgt fra gruppen bestående af hydrogen eller [(3,4-dimethoxybenzyl)oxy]methyl, guaiacolmethyl,

- 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, allyl, prenyl, *p*-methoxybenzyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl, triethylsilyl, triisopropylsilyl, *tert*-butyldimethylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, *tert*-
- 5 butyldiphenylsilyl, triphenylsilyl, acetyl, chloracetyl, phenoxyacetyl eller angeloyl.
- 5.** Fremgangsmåde ifølge krav 1, 2 eller 4 hvor R₂ er valgt fra gruppen bestående af hydrogen eller [(3,4-dimethoxybenzyl)oxy]methyl, guaiacolmethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl,
- 10 1-methyl-1-methoxyethyl, allyl, prenyl, *p*-methoxybenzyl, triphenylmethyl, 2-(trimethylsilyl)ethoxymethyl, triethylsilyl, triisopropylsilyl, *tert*-butyldimethylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, *tert*-butyldiphenylsilyl, triphenylsilyl, acetyl, chloracetyl, phenoxyacetyl eller angeloyl.
- 15 **6.** Fremgangsmåde ifølge krav 1 eller 3, hvor D er valgt fra gruppen bestående af isopropyliden, cyclopentyliden, cyclohexyliden, *p*-methoxybenzyliden, methoxymethylene, 2-oxacyclopentyliden, 2,3-dimethoxybutan-2,3-di-yl, 1,2-dimethoxycyclohexan-1,2-di-yl, octahydro-[2,2']-bipyran-2,2'-di-yl, di-*tert*-butylsilylen, 1,3-(1,1,3,3-tetraisopropylidisiloxanyliden), phenylboronat,
- 20 3-pentyliden, 2,4-dimethyl-3-pentyliden, 2,6-dimethyl-4-heptyliden, 3,3-dimethyl-2-butyliden, 1-phenyl-1-ethyliden, benzyliden, 2,4-dimethoxybenzyliden, 4-nitrobenzyliden, 2,4,6-trimethylbenzyliden, 2,2-dimethyl-1-propyliden, ethoxymethylen eller isopropoxymethylen.
- 25 **7.** Fremgangsmåde ifølge krav 6, hvor D er isopropyliden.
- 8.** Fremgangsmåde ifølge krav 1, 2 eller 4 hvor R₁ betegner en hydroxylbeskyttelsesgruppe og R₂ betegner hydrogen.
- 30 **9.** Fremgangsmåde ifølge krav 1, 2, 4 eller 5 hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV), med methylangelat, angeloylchlorid, angelinsyreanhydrid, [(*Z*)-2-methylbut-2-enoyl] 2,4,6-trichlorbenzoat eller angeloyl 4-nitrobenzoylanhydrid.

10. Fremgangsmåde ifølge krav 1, 2, 4 eller 5 hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med angeloylchlorid, angelinsyreanhydrid, [(Z)-2-methylbut-2-enoyl] 2,4,6-trichlorbenzoate eller angeloyl 4-nitrobenzoyl anhydride.

5

11. Fremgangsmåde ifølge krav 1, 2, 4 eller 5, hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med angelinsyreanhydrid:

(i) uden en katalysator; eller

10 (ii) i tilstedeværelse af en sur katalysator, for eksempel, en syre såsom perchlorsyre eller en Lewis-syre såsom scandium (III) triflat eller bismuth (III) triflat; eller

(iii) i tilstedeværelse af en base såsom natriumhydrogencarbonat, triethylamin, lithium hexamethyldisilazid, natriumhexamethyldisilazid, kaliumhexamethyldisilazid, pyridin, cæciumcarbonat eller

15 4-(dimethylamino)pyridin;

i et egnet opløsningsmiddel såsom tetrahydrofuran, MeCN, pyridin eller methyl tert-butyl ether.

20 **12.** Fremgangsmåde ifølge krav 11, hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med angelinsyreanhydrid i tilstedeværelse af en base valgt fra natriumhydrogencarbonat, triethylamin, lithiumhexamethyldisilazid, natriumhexamethyldisilazid, kaliumhexamethyldisilazid, pyridin, cæciumcarbonat og 4-(dimethylamino)pyridin.

25 **13.** Fremgangsmåde ifølge krav 1, 2, 3, 4, 5, 6, 7 eller 8, hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med et blandet angelinsyreanhydrid valgt fra angeloyl 2,4,6-trichlorbenzoylanhydrid, [(Z)-2-methylbut-2-enoyl]2,4,6-trichlorbenzoat, og angeloyl 4-nitrobenzoylanhydrid:

(i) uden en katalysator; eller

30 (ii) i tilstedeværelse af en sur katalysator under anvendelse af en syre såsom perchlorsyre eller en Lewis-syre såsom scandium (III) triflat eller bismuth (III) triflat; eller

(iii) i tilstedeværelse af en base såsom natriumhydrogencarbonat eller trimethylamin;

i et egnet opløsningsmiddel såsom toluen.

- 5 **14.** Fremgangsmåde ifølge krav 1, 2, 3, 4, 5, 6, 7 eller 8, hvor trin (b) omfatter omsætning af en forbindelse (III) eller (IV) med angeloylchlorid.

15. Fremgangsmåde ifølge krav 14, hvor esterificeringen ved omsætning med angeloyl finder sted:

- 10 i tilstedeværelse af en base såsom pyridin, triethylamin, lithiumhexamethyldisilazid eller 4-(dimethylamino)pyridin;
i et egnet opløsningsmiddel såsom pyridin eller tetrahydrofuran.

- 16.** Fremgangsmåde ifølge et hvilket som helst af kravene 1 eller 9-15, hvor
- 15 forbindelsen med den almene formel (IV) er valgt fra gruppen bestående af
Ingenol-5,20-(3-pentyliden)-ketal,
Ingenol-5,20-(2,4-dimethyl-3-pentyliden)-ketal,
Ingenol-5,20-(2,6-dimethyl-4-heptyliden)-ketal,
Ingenol-5,20-cyclopentyliden-ketal,
- 20 Ingenol-5,20-cyclohexyliden-ketal,
Ingenol-5,20-(3,3-dimethyl-2-butyliden)-ketal, Ingenol-5,20-(1-phenyl-1-ethyliden)-ketal,
Ingenol-5,20-benzyliden-acetal,
Ingenol-5,20-(4-methoxybenzyliden)-acetal,
- 25 Ingenol-5,20-(2,4-dimethoxybenzyliden)-acetal,
Ingenol-5,20-(4-nitrobenzyliden)-acetal,
Ingenol-5,20-(2,4,6-trimethylbenzyliden)-acetal,
Ingenol-5,20-(2,2-dimethyl-1-propyliden)-acetal,
Ingenol-5,20-methyl-orthoformat,
- 30 Ingenol-5,20-ethyl-orthoformat,
Ingenol-5,20-(prop-2-yl)-orthoformat,
Ingenol-5,20-(di(*tert*-butyl)silylen)-ether.